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Abstract 
 
The paired-box transcription factor 3 (Pax3), is a powerful myogenic 
regulatory factor during embryo-myogenesis. The expression of Pax3 is involved 
in determining somitic cell fate, resulting in the formation of the first 
differentiated muscle, the myotome. In addition, Pax3 expression in embryonic 
hypaxial precursor cells prevents premature differentiation, whilst promoting 
cellular migration and thus ensuring the proper development of limb muscles. 
Subsequent muscle growth in the developing embryo is provided by myogenic 
precursor cells marked by the expression of Pax3 and its paralogue, Pax7. 
Following foetal development, these precursor cells establish the distinct lineage 
of myogenic stem cells referred to as satellite cells, responsible for post-natal 
development and regeneration. However, satellite cells are not the only population 
of cells that generate myogenic precursor cells in adult muscle for regeneration 
and growth. Recently, it has been shown that in adult muscle, Pax3 is expressed in 
a population of novel, interstitial cells, and is up-regulated upon muscle injury. 
To determine the role played by Pax3 in post-natal muscle development 
and regeneration, three Pax3 over-expressing myoblast (C2C12) cell lines were 
generated and experimentally compared with control cells. Four facets of 
myoblast function were assessed: proliferation, differentiation, survival and 
migration.  
The proliferation assay showed that Pax3 over-expression significantly 
(P<0.001) slowed C2C12 myoblast proliferation, Pax3 over-expressing clones 
only reached 63% of the proliferative rate of control C2C12 cells. Furthermore, 
this study clearly showed that over-expression of Pax3 significantly (P<0.01) 
delayed the differentiation of C2C12 myoblasts. Analysis showed that following 
72 h of low serum induced differentiation 52% of the control C2C12 cell 
population had fused to form myofibres, in comparison only 16-32% of the 
myoblast population that over-expressed Pax3 had fused to from myofibres. 
Taken together, these data suggest that following satellite cell activation, Pax3 
expression could be maintained in precursor cells to expand the myogenic 
population, as their myogenic commitment is delayed by Pax3 expression and this 
would facilitate increased cell cycling, albeit at a reduced rate. Furthermore, a low 
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percentage of fusion strongly indicates a higher proportion of cells that are 
renewing the quiescent satellite cell population. 
Furthermore, over-expression of Pax3 also conferred a dose-dependent 
anti-apoptotic function to C2C12 myoblasts. Myoblasts that over-expressed a low 
level of Pax3 were more resistant to apoptosis in comparison to control C2C12 
cells and to myoblasts that over-expressed Pax3 at higher level. The anti-apoptotic 
function conferred by Pax3 expression would come into effect within the Pax3
+ 
self-renewing satellite cell lineage.  
Finally, Pax3 over-expression was shown to increase the migratory ability 
of C2C12 myoblasts. In a chemotaxis assay, there was a strong indication that an 
intermediate over-expression of Pax3 increased myoblast sensitivity to 
chemotactic signals, priming cells for migration.  The delay in differentiation also 
exhibited by Pax3 over-expression may function to allow satellite cell-derived 
progenitors to migrate to sites of injury, therefore enhancing skeletal muscle 
regenerative capacity.  
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Chapter One: Literature Review 
 
1.0 Introduction 
 
The following introduction contains a literature review on relevant past and 
current research on skeletal muscle. The paired-box transcription factor 3 (Pax3) 
is initially introduced and its involvement in embryonic myogenesis. Satellite cell 
function during post-natal growth and regeneration is then addressed; this includes 
a summary on skeletal muscle wasting and stem cell therapy. The aims and 
objectives of this study follows, stating what knowledge gaps exist and how this 
study seeks to fill some of those knowledge gaps. 
 
1.1 Paired-box transcription factor 3  
 
The Pax3 gene contains a 1437 bp cDNA open reading frame that is 
translated into a 479-amino acid protein (NM_008781), with a molecular weight 
of 56 kDa. Murine Pax3 expression is first detected at embryonic day (E) 8.5, 
corresponding to its importance in transcriptional regulation, which is 
fundamental in embryo patterning thus ensuring the correct morphological 
development of embryos (Goulding et al., 1991). Pax3 belongs to the Pax protein 
family, which includes a number of transcription factors that are indispensable for 
correct spatiotemporal gene expression during mammalian embryology (Stuart et 
al., 1994). Each Pax family member contains a 128-amino acid paired-box that 
binds as a monomer to a consensus of Pax binding sequences (Treisman et al., 
1991). Pax3 and a few other Pax proteins, including Pax7, also contain a 60-amino 
acid paired-type homeodomain; this binds as a dimer to specific recognition 
motifs that contain TAAT palindrome sequences. The initial binding of one 
homeodomain was found to synergistically increase the affinity of a second 
homeodomain binding by 300-fold (Wilson et al., 1993). Pax3 also contains an 
additional octapeptide sequence, which is conserved but has an unknown function 
(Stuart et al., 1994). The Pax3 protein can be functionally divided, whereby the N-
terminal region is responsible for inhibiting transcription, whereas the C-terminus 
binds to basal promoters for transcriptional activation: this was found to be dosage 
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dependent (Chalepakis et al., 1994). It is possible that Pax3 deals with dosage 
dependent gene expression by altering its binding characteristics via alternative 
splicing. Two isoforms of Pax3, termed Q
-
 and Q
+
, were found to be naturally 
transcribed. A cotransfection assay containing a reporter plasmid demonstrated 
that the isoforms had differential binding to specific DNA sequences that required 
the use of both sub-domains. The difference between the two isoforms is the 
presence (Q
+
) or absence (Q
-
) of a single glutamine residue within the linker 
region that joins the two sub-domains of the Pax3 protein (Vogan et al., 1996).  
As the effect of Pax3 expression is dosage dependent, alterations in its 
spatiotemporal expression can result in abnormalities (Chalepakis et al., 1994). 
There are a number of characterised mutations in Pax3, caused by point mutations, 
splice-site mutations, and chromosomal deletion that causes Waardenburg 
syndrome in humans. There are similar mutations seen in mouse Pax3, resulting in 
Splotch mouse featuring pigmentation disturbances like those witnessed in 
Waardenburg patients. The case of both conditions is attributed to the mutated 
gene affecting the migration of cells from the neural crest and thus affecting 
somitogenesis (Tassabehji et al., 1994). There are a number of conditions 
implicated with Waardenburg syndrome including deafness, with the severity of 
the condition depending on the severity of the mutation affecting Pax3 expression. 
There is also a disorder that affects musculoskeletal development, known as 
Klein-Waardenburg syndrome; patients share many of the same characteristics as 
Waardenburg patients (Hoth et al., 1993; Underhill, 2000). 
Pax3 was also found to be involved in myogenic tumours known as 
Rhabdomyosarcomas (RMS), a common malignancy in children (Kurmasheva et 
al., 2005). The majority of Alveolar Rhabdomyosarcomas (ARMS) are caused by 
a mutation that fuses the Pax3 allele to the forkhead gene (Pax3-FKHR), which 
has up to 100 times the transcriptional capacity of the wild-type Pax3 gene 
(Bennicelli et al., 1995; Bennicelli et al., 1996). These tumours are established as 
they are prevented from committing to the myogenic lineage and thus remain in 
the cell cycle as a proliferative population of myogenic progenitors (Kurmasheva 
et al., 2005), marked with the expression of MyoD (Dias et al., 1990). Pax3 
expression also offers apoptotic resistance to these tumour cells via its interaction 
with the anti-apoptotic protein BCL-XL (Margue et al., 2000). It is thought that 
the origin of ARMS is mesenchyme stem cells that have failed to commit to a 
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lineage, which matches evidence of ARMS frequency of occurrence in areas 
scarce of skeletal muscle (Anderson et al., 1999). In corroboration of this 
hypothesis, it has also been shown that Pax3 over-expression can direct the 
differentiation of multipotent mesenchyme stem cells into a myogenic lineage 
(Gang et al., 2008). 
  Pax3 misexpression is also involved in embryonic Rhabdomyosarcomas 
(ERMS), however in this case hypermethylation of CpG islands upstream of Pax3 
is considered to be the cause (Kurmasheva et al., 2005). Hypermethylation is 
linked with the suppression of gene expression, which allows the outside 
environment (epigenetic effects) to regulate development. This regulation occurs 
during normal muscle development where Pax3 expression and thus MyoD 
activation and myogenic initiation are inversely correlated to upstream CpG island 
methylation. Analysed ERMS samples showed a mean of 52% methylation in 
upstream Pax3 targets in comparison to normal muscle samples which only had a 
mean of 18% methylation (Kurmasheva et al., 2005). This demonstrates that 
ERMS cells through CpG methylation can cause the deregulation of the Pax3 
myogenic program thus resulting in tumour formation. The lower level of Pax3 
expression in ERMS can result in inadequate activation of downstream targets 
affecting terminal differentiation and promoting sustained cell cycling (Relaix et 
al., 2004). The two tumour sub-types that are caused by the misregulation of Pax3 
expression do so by two different methods, over-expression and under-expression, 
demonstrating the importance of Pax3 regulation and its level of expression 
(Kurmasheva et al., 2005).  
 
1.2 Embryonic myogenesis 
 
Myogenesis, the formation of skeletal muscle, is a highly complex and 
regulated process that requires the timely expression of a cascade of regulatory 
transcription factors that direct myogenic cell fate. The paired-box transcription 
factor Pax3, is one of the main upstream regulators of this myogenic cascade 
during primary myogenesis (Maroto et al., 1997). Activation of myogenesis 
achieved by the expression of the transcriptional networks results in the 
expression of the basic helix-loop-helix (bHLH) domain-containing myogenic 
regulatory factors (MRFs). These factors, which include myogenic factor 5 
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(Myf5), myogenic differentiation 1 (MyoD), muscle regulatory factor 4 (MRF4) 
and myogenin, are critical for myogenic progression (Pownall et al., 2002; 
Buckingham, 2006).  
 
1.2.1 Primary myogenesis  
 
There are three main phases involved in myogenesis; the primary phase is 
the formation of the first differentiated muscle, the myotome, which occurs during 
somitogenesis. Somites form in successive pairs from segments of paraxial 
mesoderm following an anterior-posterior progression on either side of the neural 
tube and notochord (Christ & Ordahl, 1995). This is followed by the somites 
differentiating into ventral and dorsal sections, known as the sclerotome and 
dermomyotome respectively (Cossu et al., 1996b). Initially somites are spheres of 
epithelial cells that will express paired-box transcription factors Pax3 and Pax7; 
however as somites mature Pax3 expression is modulated (Williams & Ordahl, 
1994). This results in the somites disaggregating into a ventral mesenchyme, 
which gives rise to cartilage for the vertebrae column and ribs (Brand-Saberi & 
Christ, 1999). The dermomyotome, which gives rise to the formation of body and 
limb skeletal muscle, will continue to express Pax3 and retain its epithelial 
structure (Williams & Ordahl, 1994).   
Pax3-expressing myogenic progenitor cells at this stage are now restricted 
to the epithelium of the dermomyotome, myogenesis is initiated with these cells 
expressing Myf5 and MRF4, resulting in cellular delamination and myotome 
formation under the dermomyotome. The myotome does not form if these specific 
MRFs are not expressed (Gros et al., 2004; Kalcheim & Ben-Yair, 2005), as these 
factors are necessary to specify myogenic commitment of the myogenic 
progenitor cells (Kassar-Duchossoy et al., 2004). Pax3 is detected in the forming 
myotome during E8.5-E10.5; the number of Pax3-expressing cells increases as the 
epithelial structure of the dermomyotome is lost.  These cells also come to express 
Pax7, with 87% of myotomal cells becoming Pax3
+
/Pax7
+
, although interestingly 
co-expression of other myogenic determination genes in this population of cells 
was not detected (Relaix et al., 2005). The remaining approximately 10% of 
myotomal cells that only express Pax3 activate the myogenic program via Myf5 
expression; consequently these cells are responsible for the myogenic 
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differentiation of the myotome (Relaix et al., 2005). Lineage-ablation studies have 
shown that myogenic specification via Myf5 expression during myotome 
formation can be compensated for by the expression of MyoD. These studies 
concluded that the absence of Myf5-expressing progenitors will result in the 
proliferative expansion of a compensatory Myf5-independent, MyoD-expressing 
myoblast lineage. The presence of two different redundantly acting myogenic 
lineages ensures the proper formation of the myotome (Gensch et al., 2008; 
Haldar et al., 2008). Downstream of Myf5 and MyoD is myogenin, which is 
responsible for the terminal differentiation of committed myoblasts. Myogenin-
null mice, although producing the usual myoblast population, lack terminal 
differentiation, resulting in perinatal death (Hasty et al., 1993; Nabeshima et al., 
1993). Thus, the correct spatiotemporal expression of the MRFs during myotome 
formation results in committed, terminally differentiated myoblasts fusing to form 
multinucleated primary myotubes; this is known as primary myogenesis. This 
initial muscle structure grows through secondary myogenesis, where the existing 
myotubes act as a template for secondary myoblasts to fuse with. The resulting 
secondary myotubes subsequently fuse to form myofibres and thus produce the 
functional muscle (Gullberg et al., 1998). The formation of the myotome during 
murine embryonic development is represented in Figure 1.1.  
As the myotome forms, Pax3 expression is further adjusted as the 
dermomyotome/myotome delineates into epaxial and hypaxial domains (Goulding 
et al., 1994). This modulation of Pax3 expression is caused by up-regulation of 
miR-27, which interferes with Pax3 expression and allows for myogenic 
differentiation of progenitor cells (Crist et al., 2009). The epaxial domain gives 
rise to back musculature, while the hypaxial domain gives rise to the muscle of the 
rest of the body and limbs (Brand-Saberi et al., 1996). Interestingly, smooth 
muscle and skeletal muscle arise from the same clonal origin, that is, the Pax3 
progenitors present in the central epithelium of the dermomyotome (Esner et al., 
2006). During delineation the signalling factor N-cadherin controls Pax3 
progenitor cell fate; initially it is expressed in both cell types, progenitors of 
smooth and skeletal muscle, to conserve the integrity of the epithelium. However, 
as the structure delineates and the epithelium breaks down, N-cadherin is only 
expressed in apical cells entering the myotome, thus promoting a terminally 
differentiated myogenic program (Cinnamon et al., 2006). Within the epaxial 
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domain, Pax3 expression is down-regulated as the transcriptional activators of 
MyoD are turned on for myogenic differentiation. However, Pax3 expression is 
continued in the hypaxial domain as MyoD is repressed, allowing for limb muscle 
precursor cell migration. This was observed in studies performed on homozygous 
Splotch mutant mice, which fail to develop limb muscles as the Pax3 protein is not 
synthesised (Bober et al., 1994; Goulding et al., 1994; Williams & Ordahl, 1994), 
which also results in increased apoptosis of hypaxial progenitor cells (Dickman et 
al., 1999). 
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1.2.2 Limb myogenesis  
 
Myogenic progenitor cells of the limb arise from the limb bud level of the 
hypaxial domain. They migrate to dorsal and ventral positions where the muscle 
masses will form, which is highly regulated by a number of homeobox genes 
(Christ & Ordahl, 1995; Tajbakhsh & Buckingham, 2000). Similar to the Pax3-
null condition, embryos null for the tyrosine kinase receptor c-met and its ligand 
scatter factor/hepatocyte growth factor (SF/HGF) result in cell migration defects 
producing similar muscle phenotypes (Yang et al., 1996). The combined 
expression of c-met and SF/HGF is required for dermomyotome cellular 
delamination as well as having implications in guiding migration (Birchmeier & 
Brohmann, 2000), with HGF expression possibly being involved in lamellipodia 
formation (Salerno et al., 2009). Pax3 regulates the expression of these genes, 
with their expression being severely compromised in the absence of Pax3 (Epstein 
et al., 1996; Birchmeier & Brohmann, 2000). An additional factor, Lbx1 is 
expressed in limb muscle progenitor cells prior to and during migration, playing a 
major role in ensuring the correct long-range migration of cells (Buckingham, 
2001). This was confirmed by Lbx1-null mice embryos, which exhibited forelimb 
muscle abnormalities and a lack of hindlimb muscle, with no evidence to indicate 
premature differentiation or inefficient delamination (Brohmann et al., 2000; 
Gross et al., 2000).  
Once the progenitor cells reach their target sites, the myogenic process is 
coordinated by several MRFs.  Initially, the myogenic determination gene Myf5 is 
expressed, which in the hypaxial somite and limb buds has been shown to be 
directly activated by Pax3 (Bajard et al., 2006). The Pax3/Myf5 interplay causes 
the precursor cells to form into myoblasts and undergo extensive proliferation 
before the skeletal muscle forms (Delfini et al., 2000). Proliferating cells were not 
seen to express MyoD, and MyoD was not activated until post-mitotic cells 
activated the differentiation program, suggesting that Pax3 and Myf5 are 
genetically upstream of MyoD (Tajbakhsh et al., 1997; Bajard et al., 2006). 
Differentiation can be delayed by the expression of the homeo-box factor Msx1, 
which promotes proliferation by keeping myoblasts dividing (Houzelstein et al., 
1999). Following proliferation, the myoblasts differentiate in response to the 
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expression of myogenic differentiation factors, including myogenin and Mef2 
(Buckingham et al., 2003).  
 
1.2.3 Embryonic myogenic signalling pathways 
 
 As mentioned previously, Pax3 is one of the main upstream genes that 
regulate lineage specification during primary myogenesis, being globally 
expressed prior to myogenic commitment (Williams & Ordahl, 1994). Protein 
activity from members of the family sineoculis homeobox (SIX) and eyes absent 
homologue (EYA) are responsible for regulating Pax3 expression, as well as 
independently binding to MRF regulatory sequences. Expression of SIX1 and 
SIX4, in conjunction with its cofactors EYA1 and EYA2, induces Pax3 
expression and can bind in parallel to the hypaxial enhancer element to initiate 
Myf5 and Mrf4 expression (Grifone et al., 2007). Whereas, in the epaxial domain, 
the SIX protein family controls MRF4 expression independently in addition to 
enhancing MyoD and myogenin expression, thus promoting terminal 
differentiation (Grifone et al., 2005).  
The development of the dermomyotome and the specification of myogenic 
precursor cells are also influenced by signalling molecules produced by tissues 
neighbouring the paraxial mesoderm (Cossu et al., 1996a; Brand-Saberi, 2005).  
Epaxial muscle specification requires activating cues from axial structures such as 
the neural tube and notochord.  For example, it was found that the neural tube acts 
as a positive activator of myogenesis through the Myf-5-dependent pathway 
(Cossu et al., 1996a).  When myogenesis has been initiated the notochord secretes 
the signalling molecule Sonic hedgehog (SHH), which maintains Myf5 expression 
by binding to the early epaxial enhancer, a Myf5 regulatory sequence (Gustafsson 
et al., 2002). The neural tube and surface ectoderm are also responsible for Wnt 
signalling; a complex network of proteins involved in regulating embryonic 
development, producing Wnt1 and Wnt7a respectively, which preferentially 
induce myogenesis via Myf5 and MyoD, respectively, through the β-catenin 
pathway (Tajbakhsh et al., 1998). In the epaxial domain in the absence of Myf5 
and MRF4, MyoD is still expressed, as shown by Myf5/MRF4 double-mutant 
studies (Tajbakhsh et al., 1997). However, if protein kinase C (PKC) inhibitor is 
present, MyoD expression is blocked, indicating that Wnt signalling is dependent 
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on the PKC-pathway. When a more constitutively active form of Pax3 was 
expressed, the Pax3-FKHR gene, MyoD expression was not affected, suggesting 
that Wnt signalling acts on Pax3 induction (Brunelli et al., 2007). The myogenic 
induction pathways mentioned above are illustrated in Figure 1.2. 
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On the other hand, axial structures are not required for the determination 
of hypaxial muscle precursor cells as they are required to migrate to the limb buds 
and body wall before differentiating to form muscle (Cossu et al., 1996a).  
Nevertheless hypaxial muscles do require signals from the surface ectoderm and 
lateral mesoderm to negatively regulate myogenic induction, allowing for the 
correct specification of migrating progenitor cells (Gullberg et al., 1998). In vitro 
studies performed by Cossu et al. (1996a) showed that the dorsal ectoderm also 
induces myogenic differentiation through a MyoD-dependent pathway, yet in 
vivo, the dorsal ectoderm initially does not express any member of the MyoD 
family.  However, if the lateral plate is mechanically separated from the paraxial 
mesoderm within a chick embryo then MyoD expression is seen in the hypaxial 
domain where it is not normally observed (Pourquie et al., 1995), thus indicating 
that the lateral plate releases signals that are responsible for repressing myogenic 
differentiation of hypaxial muscle precursor cells.  It was found that cells 
expressing bone morphogenic protein-4 (BMP-4) can replace the inhibitory action 
of components expressed by the lateral plate mesoderm (Pourquie et al., 1996).  
This implicates BMP-4 as a possible negative signal secreted by the lateral plate 
mesoderm that requires derepression for myogenesis to proceed. Fibroblast 
growth factors (FGFs) are also known to be secreted during myotome formation, 
resulting in a proliferative non-differentiated population (Haub & Goldfarb, 
1991). Both BMP-4 and FGFs are thought to be regulated in a derepression 
fashion, resulting from Notch/Delta signalling or from antagonist Noggin action 
that activates a repressed myogenic programme (Yun & Wold, 1996; Tajbakhsh & 
Cossu, 1997).  
 
1.2.3 Secondary myogenesis  
 
 In the following sections, Pax gene expression, in the context of 
myogenesis, refers to Pax3 and Pax7 gene expression. Following somite 
patterning, myotome formation and hypaxial precursor muscle migration, there is 
a period of exceptional muscle growth, known as the second myogenic phase 
(Bryson-Richardson & Currie, 2008). It was originally thought that a highly 
proliferative, non-differentiated population of cells provided the myonuclei for 
muscle growth. In 2005, a population of myogenic precursor cells were 
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discovered that co-express Pax3 and Pax7; these cells originate from the early 
dermomyotome during somite maturation and epithelial disintegration (Kassar-
Duchossoy et al., 2005; Relaix et al., 2005). These highly proliferative cells are 
distinct from myogenic cells and were also found in the limb buds, originating 
from the hypaxial domain of the dermomyotome. Generally these cells remain 
highly proliferative as they don‟t express any specific muscle markers, and are 
considered somitic stem cells (Zammit, 2008). However, they can become 
incorporated into muscle fibres by activating Myf5 and MyoD expression (Ben-
Yair & Kalcheim, 2005; Gros et al., 2005; Kassar-Duchossoy et al., 2005; Relaix 
et al., 2005). Thus, these cells provide a reservoir of myogenic precursor cells that 
maintain muscle growth throughout foetal development. This was confirmed by 
Pax3 and Pax7 double mutant studies, which resulted in only skeletal muscle from 
the early myotome forming, failing to provide muscle mass growth for secondary 
myogenesis (Relaix et al., 2005). Without Pax expression, these cells failed to 
activate myogenic determination genes, thus adopting other cell fates as the 
myogenic programme is not activated (Borycki et al., 1999). Derivatives of the 
ventral somite, bone and cartilage, as well as adipose tissue, are default pathways 
in the absence of myogenic commitment (Rudnicki et al., 1993). Also, as both 
Pax3 and Pax7 play a role in ensuring cell survival, the majority of cells that don‟t 
assume other cell fates will apoptose (Borycki et al., 1999; Kassar-Duchossoy et 
al., 2005).  
These Pax-positive cells that provide muscle growth during foetal 
development and are found in all developing muscle masses will establish 
themselves as satellite cells in the peri-natal period. These cells have stem cell-
like properties and are responsible for post-natal growth and regeneration (Gros et 
al., 2005) and in a quiescent state will take up position under the basal lamina that 
forms around muscle fibres (Buckingham, 2007). The Pax-positive derived 
satellite cells account for over 90% of satellite cells present at birth, while the 
remainder is accounted for by stem cells in adjacent structures that are recruited 
following injury (Sampaolesi et al., 2003). The Pax-positive cells that satellite 
cells originate from also contribute to production of a heterogeneous population of 
muscle stem cells. This depends on whether a distinct population of Pax-
expressing cells (approximately 80%) express Myf5 during peri-natal 
development before re-entering the quiescent state (Beauchamp et al., 2000; Day 
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et al., 2007), as Myf5 is a direct target of Pax3 (Bajard et al., 2006). As these cells 
are capable of self-renewal via asymmetric division, there are two resulting 
populations of cells, Pax
+
/Myf5
-
 or Pax
+
/Myf5
+
. The two populations result in 
different capabilities, as Pax
+
/Myf5
-
 exhibit more stem-like properties and are 
more inclined to maintain satellite cell numbers via asymmetric cell division. 
Whereas Pax
+
/Myf5
+
 cells have properties similar to committed progenitors 
disposed towards terminal differentiation but are less efficient at regenerating 
muscle (Kuang et al., 2007).  
There are many signalling pathways involved in stem cell maintenance, 
and determination of whether specific stem cells are pushed into a program of 
differentiation or maintained as stem cells. During embryo-myogenesis, the family 
of fibroblast growth factors (FGF) have been indicated to regulate Pax-positive 
stem cell fate, especially Fgfr4 (Lagha et al., 2008a). FGF signalling is involved 
in regulating myogenesis, with consequent effects of promoting the proliferation 
(von Scheven et al., 2006) and differentiation of myoblasts (Hammond et al., 
2007). Specific Fgfr4 expression is detected at myogenic sites from actively 
dividing myoblasts (Stark et al., 1991), with down-regulation of expression 
(Edom-Vovard et al., 2001) or expression of dominant-negative Fgfr4 (Marics et 
al., 2002) resulting in preventing the expression of myogenic genes Myf5, MyoD 
and MyHC. However, knocking out the Fgfr4 gene does not result in lethality; 
myogenesis proceeds normally in the embryo, indicating that other members of 
the FGF family can act as redundant receptors (Weinstein et al., 1998). Chromatin 
immunoprecipitation experiments were used to demonstrate that Pax3 lies 
genetically upstream of Fgfr4 and controls its expression during myogenesis via 
the 3‟ regulatory element of FgFr4. In the differentiating progeny of Pax-positive 
cells, in which Pax3 is down-regulated, Fgfr4 signalling is further modulated and 
controlled by MyoD, which binds to an E-box within the 3‟ regulatory region. In 
addition, in a myogenic context, Pax3 also controls the expression of sprouty1, 
involved in the Fgfr4 signalling pathway. This led Lagha et al (2008a) to propose 
that Pax3, via Fgfr4 signalling, controls the myogenic cell fate of Pax-positive 
expressing cells. Interfering with Fgfr4 signalling by either up-regulating sprouty1 
or interrupting signalling with Fgf8 expression, a potential Fgfr4 ligand 
(MacArthur et al., 1995), results in preventing differentiation and increasing the 
stem cell pool of Pax
+
/Myf5
-
 cells (Hammond et al., 2007).   
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During primary myogenesis, Pax3 plays the predominant role of 
transcriptional regulator of myogenic progression (Tajbakhsh et al., 1997). As 
development proceeds into the late neo-natal/early peri-natal stages, the 
Pax3/Pax7 positive cells that become satellite cells result in a hierarchy shift 
towards Pax7 expression. Although dispensable during early myogenesis, Pax7 
expression is a requisite for satellite cell maintenance (Seale et al., 2000; 
McFarlane et al., 2006). In addition, in adult muscle satellite cells the anti-
apoptotic function acquired by Pax7 expression cannot be compensated for by 
Pax3 (Relaix et al., 2006). Illustrated in Figure 1.3 is the lineage progression of 
the Pax-positive somatic stem cells that are responsible for the secondary phase of 
myogenic growth and development and for establishing the satellite cell pool.  
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1.3 Post-natal myogenesis  
 
The last myogenic phase comprises maintenance and growth of post-natal muscle. 
As muscle cells are incapable of division, the nuclei for growth, regeneration and 
repair are acquired from satellite cells.  First discovered in 1961 (Mauro, 1961), 
these cells are now accepted as being muscle stem cells, as once activated they are 
capable of providing a proliferating and differentiating population of progenitors 
that maintain cell numbers via self-renewal (Collins et al., 2005). In early post-
natal mouse muscle, 30-35% of the sublaminal nuclei are contributed by satellite 
cells. This number drops to only 1-4% by adulthood as the satellite cells are only 
required to provide the myonuclei for growth and regeneration (Allbrook et al., 
1971). As in primary myogenesis, post-natal myogenesis follows a highly 
orchestrated genetic program that initiates either repression or induction 
depending on cell-cycle progression and external cues (Charge & Rudnicki, 2004; 
Zammit et al., 2006b). Recently, in vivo research using a murine model has 
indicated that the dependency of myogenic progenitor cells on Pax-regulation 
during skeletal muscle development and regeneration is only maintained until 
juvenile development, at which stage post-natal muscle regeneration proceeds in 
the absence of Pax-regulation (Lepper et al., 2009). To the contrary, reviewed 
below are numerous studies, which indicate both Pax3 and Pax7 regulation of 
post-natal regeneration processes.  
 
1.3.1 Satellite cell physiology 
 
As the Pax-positive cells of secondary myogenesis form into quiescent 
satellite cells, Pax7 becomes the main satellite cell marker (Halevy et al., 2004). 
Pax3 in comparison is down-regulated, with transient expression only seen during 
the activation of the proliferating progeny of satellite cells in most muscles 
(Conboy & Rando, 2002; Day et al., 2007). On the contrary, Pax3 expression is 
also detected in quiescent satellite cells in certain muscle types such as the 
diaphragm and a subset of the trunk and limb muscles (Relaix et al., 2006). This 
was confirmed by using a (Pax3)GFP
+
 mouse line to isolate satellite cells from 
skeletal muscle, using flow cytometry. The (Pax3)GFP
+
 mouse line showed 
localised spatial expression as quiescent Pax3 positive satellite cells. Flow 
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cytometry led to the isolation of a homogenous Pax7
+
, CD34
+
, CD45
-
, Sca1
-
 cell 
population that show regenerative capacity when grafted into the tibialis anterior 
muscle of immunodeficient mdx (dystrophin-deficient) mice (Montarras et al., 
2005).  
Stem cell antigen-1 (Sca1) was first identified as an antigen that allowed 
for bone marrow stem cell purification (Spangrude et al., 1988). This membrane 
protein, which is not initially expressed by satellite cells, is expressed by a subset 
of satellite cell-derived myoblasts, with differentiation inducing a marked up-
regulation of expression (Shen et al., 2003). This results in a heterogeneous 
myoblast population: Sca1
-
 myoblasts are highly proliferative and inclined to 
differentiate, providing myotubes for growth, whereas, Sca1
+
 myoblasts maintain 
cells in a non-differentiated, slowly proliferating state that could be involved in 
satellite cell renewal (Mitchell et al., 2005). On the other hand, CD34 is initially 
expressed by satellite cells and was found to be a marker of satellite cell 
quiescence (Beauchamp et al., 2000). A member of the sialomucin family of 
surface molecules, CD34 has identified functions involved in haematopoietic cell 
differentiation and cell-cell adhesion (Krause et al., 1996). The quiescent satellite 
cells that express CD34 were also found to express Myf5, indicating that CD34 
marks satellite cells that are committed to the myogenic lineage (Beauchamp et 
al., 2000). Furthermore, CD34
+
 satellite cell-derived myoblasts, in comparison to 
CD34
-
 myoblasts, had a higher capacity to replace dystrophin in mdx mice 
(Jankowski et al., 2002). These two markers, Sca1 and CD34, can possibly be 
used to define and separate the two satellite cell lineages based on their myogenic 
regenerative capacity or ability to self-renew (Jankowski et al., 2002). Occupy 
Other genes that satellite cells express include the tyrosine kinase receptor, 
c-met. Present in both quiescent and activated satellite cells as well as derived 
mono-nucleated muscle cells (Cornelison & Wold, 1997) c-met is thought to be 
involved in mediating satellite cell activation (Allen et al., 1995). N-cadherin and 
M-cadherin are cell-adhesion proteins that allow communication with the 
underlying myofibres (Irintchev et al., 1994). M-cadherin was found to be 
expressed in 94% of cells between the basal lamina and the underlying myofibre 
(Sajko et al., 2004). Underlying myofibres are part of a unique niche that 
surrounds satellite cells and occupation of this niche is used to identify satellite 
cells, as their molecular signature is hard to distinguish from that of myoblasts 
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(Yablonka-Reuveni, 1995). Furthermore, this niche is an important regulator of 
satellite cells, providing a dynamic micro-environment that can either maintain 
quiescence or provide cues for activation (Zammit, 2008). The importance of the 
niche was shown by transplantation experiments where intact myofibres 
containing as little as seven satellite cells were transplanted into radiation-ablated 
muscle. The myofibre niche provided the cues for these satellite cells to be self-
sufficient, generating thousands of myonuclei for growth as well as repopulating 
the original host muscle stem cell population (Collins et al., 2005). The niche 
contains diffusible factors, such as hepatocyte growth factor (HGF), which is 
present in the overlying basal lamina in both pro and active form. Proteolytic 
cleavage provides an abundance of pro-HGF, which is released to activate satellite 
cells when a muscle is stretched or injured (Tatsumi & Allen, 2004). Furthermore, 
Notch signalling, which responds to Notch ligands that the underlying myofibres 
present during growth or injury, is also involved in satellite cell activation 
(Conboy et al., 2003). In primary myoblast cultures, Notch signalling has been 
shown to activate transient Pax3 expression, which is detected upon satellite cell 
activation (Conboy & Rando, 2002). Interestingly, it is actually degeneration in 
the satellite cell niche, rather than of the actual stem cell, that is responsible for 
loss of regenerative capacity in old muscle (Conboy et al., 2005). Deregulation 
can be caused by insufficient presentation of delta ligands for Notch signalling 
(Conboy et al., 2003). Research found that exposure of aged satellite cells to the 
systemic factors present in serum from young cells rejuvenated the lost 
regenerative capacity of the aged satellite cells (Conboy et al., 2005).  
 
1.3.2 Satellite cell regulation  
 
Quiescent satellite cells will reside under the basal lamina of the muscle 
fibre until the skeletal muscle stretches or is injured; this subsequently activates 
the quiescent cells (Zammit et al., 2006a). Release of active HGF ligand during 
injury interacts with the active c-met receptor expressed by satellite cells, inciting 
their activation. This release is mediated as it is proportional to muscle damage 
(Tatsumi et al., 1998). Active HGF was found to be the first molecule to induce 
DNA synthesis in satellite cells when compared to an array of growth factors, and 
thus initiates the cell cycle (Gal-Levi et al., 1998). Experimental exogenous 
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injection of purified pro-HGF confirmed the role of HGF, as it activated quiescent 
satellite cells in undamaged rat muscle (Tatsumi et al., 1998), with a dosage-
dependent increase amplifying the proliferative rate of progenitor cells (Gal-Levi 
et al., 1998). Also, as part of satellite cell activation, HGF expression results in the 
down-regulation of caveolin-1, a marker for satellite cell quiescence (Volonte et 
al., 2005). However, HGF would seem to be temporally regulated; although 
exogenous injection into already regenerating muscle increases the active satellite 
cell pool, the regenerative potential did not increase. The subsequent reduction in 
regenerative capacity comes from inhibition of differentiation by HGF (Miller et 
al., 2000). This inhibition of differentiation was confirmed by ectopic expression 
of HGF inhibiting the expression of MRFs such as MyoD, myogenin and MyHC, 
with ectopic expression of MyoD reversing this inhibitory effect (Gal-Levi et al., 
1998). Curiously, HGF and c-met, which are genetically downstream of Pax3, 
exhibit a similar effect of inhibiting myogenic differentiation during embryo-
myogenesis to allow for somatic limb migration (Lagha et al., 2008b). In support, 
studies have shown that over-expression of Pax3 does inhibit the differentiation of 
C2C12 cultured myoblasts (Epstein et al., 1995) as well as inhibiting the 
differentiation of satellite cell-derived myoblasts (Collins et al., 2009). 
HGF is not the only molecule to play a role in satellite cell activation, as 
there are many other candidates, such as the insulin-like growth factors (IGF)-I 
and -II (Goldspink, 2002). IGF-I activates satellite cells and causes hypertrophy 
by stimulating myoblast proliferation and differentiation (Florini et al., 1996), 
whereas, IGF-II affects differentiation in a dose-dependent manner. At low 
concentrations IGF-II stimulates differentiation, however, as it is up-regulated, 
differentiation is inhibited (Florini et al., 1996). In addition, the temporal 
regulation of IGF-II is important: if it is expressed initially after injury than there 
is a delay in regeneration. In comparison, if it is expressed during fibre 
enlargement then it enhances late regeneration (Kirk et al., 2003). There are also 
two splice variants of the IGF-I gene, both of which are specifically expressed by 
injured or stretched muscles. The splice variant known as “mechanosensitive 
autocrine growth factor” (MGF) acts as the initial satellite cell activator, and is 
expressed directly after injury to activate and enhance proliferation. The second 
splice variant, IGF-IEa, which is more similar to its parent protein, is responsible 
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for maintaining protein synthesis during late regeneration to finish restoration 
(Yang & Goldspink, 2002; Hill & Goldspink, 2003). 
The FGF family, which is involved in regulating progression and fate of 
embryo-myogenic stem cells, may also play a role during post-natal myogenesis. 
Within the embryo, Pax3-regulated sprouty1/Fgfr4 interplay suggests that 
sprouty1 prevents premature differentiation by negatively regulating Fgfr4 
signaling (Hammond et al., 2007), as mentioned in Section 1.3.4. A similar 
expression profile was discovered for satellite cells, as quiescent satellite cells 
express sprouty1 and Fgfr4, however following activation only Fgfr4 was 
expressed (Fukada et al., 2007). The down-regulation of sprouty1 during satellite 
cell activation coincides with the global expression of MyoD, a sign of satellite 
cell entry into the myogenic program (Kastner et al., 2000). Fgfr4 signalling is not 
only seen in activating satellite cells but also in regenerating muscle following 
injury (Zhao & Hoffman, 2004), with Fgfr4-null mice demonstrating defects in 
muscle regeneration. During in vivo muscle regeneration, Fgfr4 signalling was 
highly expressed during myoblast withdrawal from the cell-cycle and during the 
subsequent fusion to form multinucleated myotubes (Zhao et al., 2006). In 
comparison to embryonic muscle, the regenerating muscle of Fgfr4-null mice has 
a much more evident phenotype showing reduced efficiency in myogenic terminal 
differentiation. Interestingly, after only one round of degeneration/regeneration, 
Fgfr4-null mouse muscle was calcified, as well as being replaced by adipose fat. 
These processes have been documented occurring in chronic inflammatory states 
and in human dystrophic muscle, however, only after years of degeneration and 
regeneration (Zhao et al., 2006). Furthermore, the transcriptional pathway for 
Fgfr4 signalling during post-natal muscle regeneration was found to be under the 
control of MyoD. MyoD activates a transcriptional enhancer factor Tead2 which 
in turn induces Fgfr4 expression via binding to an M-CAT motif in the Fgfr4 
promoter region (Zhao et al., 2006). The importance of Fgfr4 signalling during 
post-natal myogenesis has been demonstrated, with absence of Fgfr4 expression 
resulting in myogenic cells seeking alternative paths of differentiation, 
undermining muscle regeneration.  
 Where satellite cell-derived myogenic cells require FGF signalling for 
efficient terminal differentiation, Notch signalling on the other hand prevents 
premature differentiation. Notch signals through Delta ligands that bind to their 
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corresponding Notch receptors, resulting in the release of the Notch intracellular 
domain (NCID) via proteolytic cleavage. The NCID relocates to the nucleus 
where the transcription factor RBPJ mediates its signal for the activation of genes 
that prevent uncontrolled differentiation, thus regulating proliferation and cell fate 
(Vasyutina et al., 2007a).  The importance of Notch signalling and its mediator 
RBPJ was shown by a conditional RBPJ knockout in somatic cells, which resulted 
in the incorrect temporal expression of myogenic differentiating genes. 
Furthermore, it resulted in the depletion of the Pax-positive derived satellite cell 
pool, thus severely affecting future development of muscle tissue. This underlines 
the importance of RBPJ-mediated Notch signalling in maintaining and developing 
the satellite cell pool (Vasyutina et al., 2007b). In post-natal myogenesis the 
Notch-1 receptor is expressed by satellite cells during activation, with continued 
expression promoting proliferation and preventing differentiation (Conboy & 
Rando, 2002). To allow for myogenic differentiation of the proliferating progeny, 
Numb (an inhibitor of Notch) is expressed which prevents the nuclear 
translocation of NCID and thus interrupts Notch signalling, thus permitting 
myogenic commitment (Nofziger et al., 1999). It has been indicated that Notch 
signalling is involved in ensuring satellite cell self-renewal facilitated by the 
asymmetric distribution of Numb during cell division. This could result in 
daughter cells having divergent fates, either becoming a terminally-differentiated 
myogenic cell or self-renewing to maintain satellite cell numbers (Conboy & 
Rando, 2002; Shinin et al., 2006). This was further confirmed by inhibiting the 
proteolytic cleavage of Notch receptors via DAPT, a γ-secretase-inhibitor, 
creating a differentiating phenotype marked by the repression of Pax7 (Kuang et 
al., 2007). There is no evidence at this time to indicate that Notch signalling is 
regulated by the Pax genes and thus this pathway must be modulated by extrinsic 
myogenic controls. These extrinsic factors also seem to control the expression of 
members of the Transforming growth factor-beta (TGF-β) superfamily, which 
have roles in regulating myogenic progression (Lagha et al., 2008b). 
The first member of this family, named TGF-β, which the TGF-β 
superfamily of proteins was named after, was shown in a dose-dependent manner 
to inhibit differentiation and reduce proliferation of satellite cells, with the 
inhibitory effect being reversible (Allen & Boxhorn, 1987). The experiment was 
then repeated in the presence and absence of FGF and IGF-I, to test the effect of 
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these mitogens in regulating myogenic progression of satellite cells. It was found 
that the addition of these specific mitogens can restore the proliferative potential 
of satellite cells treated with TGF-β, however differentiation inhibition was 
maintained. This indicates that during post-natal myogenesis the expression of 
TGF-β prevents premature differentiation, with the combined expression of 
mitogens inducing the proliferative expansion of satellite cells. Furthermore, by 
altering the concentrations of the three different factors  (TGF-β, IGF-I and FGF) 
the myogenic progression of satellite cells in vitro can be controlled and 
maintained throughout proliferation, differentiation or quiescence (Allen & 
Boxhorn, 1989).  
Myostatin (Mstn) is a member of the TGF-β superfamily and is a negative 
regulator of myogenesis. Its role is confirmed by its own naturally occurring 
mutation that results in a double-muscled phenotype, as seen in the Belgian Blue 
and Piedmontese cattle (Kambadur et al., 1997; McPherron et al., 1997). 
Myostatin is initially expressed as a 52 kDa precursor protein that is 
proteolytically cleaved and secreted by myoblasts as a 26 kDa mature peptide 
(Thomas et al., 2000; Arnold, 2001). The addition of this mature peptide to 
C2C12 myoblasts in vitro results in inhibition of proliferation via arrest of cell 
cycle progression at the G1-phase. This is caused by Mstn up-regulating p21, 
inhibiting cyclin-CDK activity and increasing the amount of hypophosphorylated 
Rb protein, which in turn is responsible for cell cycle arrest. Thus, the excessive 
hyperplasia seen in Belgian Blue and Peidmontese cattle is a result of unregulated 
myoblast proliferation (Thomas et al., 2000). In an additional study, Mstn was 
also shown to inhibit the differentiation of C2C12 myoblasts. Transcriptional 
analysis of C2C12 cells in low serum medium treated with Mstn showed reduced 
levels of the myogenic determination genes and p21, thus preventing myogenic 
differentiation. However, this resulted in increased phosphorylation levels of 
Smad3, a protein involved in the TGF-β signalling cascade (Zhang et al., 1998), 
as well as amplified Smad3 association with MyoD, indicating that Mstn inhibits 
differentiation by reducing MyoD activity. This was confirmed by using a 
dominant-negative Smad3-expressing construct, which recovered MyoD activity. 
Therefore, Mstn can be seen as a powerful regulator that controls the amount of 
hyperplasia and hypertrophy that occurs during post-natal growth by controlling 
the myogenic progression of myoblasts (Langley et al., 2002).   
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The up-regulation of p21 caused by the expression of Mstn, as seen in 
C2C12 cells, also occurs in satellite cells, preventing their progression from the 
G1- to S-phase in the cell cycle. This blocks satellite cell activation and thus the 
expression of Mstn promotes a quiescent state. Also, using CD34 as a marker, 
immunohistochemical analysis demonstrated that Mstn-null mouse muscle fibres 
had an increased number of satellite cells per unit length in comparison to 
wildtype. This could be due to the increased proliferative rate procured in the 
absence of Mstn, with delayed myogenin expression allowing for a boost in self-
renewal (McCroskery et al., 2003). The role of Mstn in regulating satellite cell 
activity was further investigated by comparing wildtype and Mstn-null mice 
treated with notexin (a potent neurotoxin obtained from snake venom). Two days 
after injury, in areas of regeneration, Mstn-null mice showed a dramatic increase 
in the number of migrating satellite cells and the number undergoing myogenic 
commitment via MyoD expression. In addition, increased numbers of 
macrophages were found in notexin treated Mstn-null mice, with an increased 
inflammatory response reducing the amount of inflamed tissue. In the absence of 
Mstn within regenerated muscle there was evidence to indicate a more complete 
healing with less fibrosis (McCroskery et al., 2005). The negative regulation of 
satellite cell function exhibited by Mstn has been shown to act via a negative 
regulation of Pax7 expression. This in turn both affects the activation of MyoD 
expression as well as the ability of satellite cells to withdraw from the cell cycle to 
renew the stem cell population. Consequently, if Mstn expression is blocked, a 
Pax7 over-expressing phenotype occurs which amplifies the self-renewing 
satellite cell lineage (McFarlane et al., 2006). 
 
1.3.3 Satellite cell function 
 
The expression of the Pax genes maintains satellite cells in a quiescent 
state as these genes repress MyoD. In response to growth or injury, growth factors 
from the surrounding extracellular environment activate satellite cells (Zammit et 
al., 2006b). Intermediate progenitor cells are marked by Pax3 expression, which 
represses continued myogenic progression (Conboy & Rando, 2002). Pax3 is 
regulated by ubiquitination, which results in proteasomal degradation of Pax3, 
allowing intermediate progenitors to develop into myogenic progenitors. 
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Interestingly, this proteasomal degradation pathway does not affect the Pax7 
protein, as its expression is maintained (Boutet et al., 2007). Pax3 expression can 
also be fine tuned by miRNA interference. Prior to satellite cell progenitor 
differentiation, miR-27 is up-regulated to negatively regulate Pax3 protein 
synthesis (Crist et al., 2009). Subsequently, MyoD will be expressed in the 
corresponding proliferating progeny as well as increased Myf5 expression, which 
is already activated in the majority of satellite cells. Pax7 has been shown to 
modulate Myf5 expression by interacting with the methyltransferase complex 
resulting in chromatin modifications and transcriptional activation (McKinnell et 
al., 2008). Up-regulated Myf5 transcription leads to the down-regulation of Pax7, 
and activation of myogenin, marking cellular differentiation. This is followed by 
cell-cycle withdrawal and myoblast fusion with pre-existing multinucleated 
myotubes, providing hypertrophy for regeneration. Also, differentiating myoblasts 
can fuse together to form new myotubes, supplying hyperplasia for growth 
(Hawke & Garry, 2001; Halevy et al., 2004; Zammit et al., 2006b). Alternatively, 
following proliferation, satellite cell-derived myoblasts can change their cell fate 
by down-regulating MyoD while continuing to express Pax7, leading to cell-cycle 
withdraw. Using this alternative path, a small sub-population of satellite cell 
progeny can revert to their quiescent satellite cell status and thus maintain satellite 
cell numbers (Zammit et al., 2004).  
MyoD expression can be prolonged into and during differentiation if the 
progeny are growing within a rich, high mitogen media, as myoblasts still have 
proliferative potential during the early phases of differentiation (Yablonka-
Reuveni & Paterson, 2001; Shefer et al., 2006). Post-translational modifications, 
repressor proteins and epigenetics controlling DNA accessibility all regulate 
MyoD and can increase the proliferative period before differentiation is induced 
(Berkes et al., 2004). Pax3/Pax7 is thought to regulate MyoD expression. This 
was shown by using cultured satellite cells expressing dominant-negative forms of 
Pax3 and Pax7, resulting in a Myf5-directed differentiation pathway. 
Differentiation was marked by a delay in myogenin expression, due to the 
consequent down-regulation of MyoD (Relaix et al., 2006; Zammit et al., 2006b). 
Furthermore, when dominant-negative forms of Pax3 and Pax7 were expressed 
within the Myf5 negative satellite cell line mentioned above (Kuang et al., 2007) 
there was no differentiation, indicative that the Pax genes regulate myogenesis 
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through MyoD (Relaix et al., 2006). As described above and in Section 1.3.2, the 
progression of satellite cells and their function in regenerating post-natal muscle is 
a highly regulated process that results in introducing population heterogeneity 
(Figure 1.4) (Buckingham & Montarras, 2008). 
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1.3.4 Satellite cell self-renewal 
 
The ability to replenish the quiescent satellite cell pool is a requirement 
fulfilled by satellite cells, meaning they fit the stem cell definition. Following the 
lineage progression from satellite cells to differentiating satellite cell-derived 
myoblasts involves cell multiplication via symmetric division and self-renewal 
through asymmetric division (Shinin et al., 2009). DNA tracking during the S-
phase demonstrated that satellite cell division can be asymmetrical, resulting in 
both quiescent satellite cells and myonuclei for growing muscle (Moss & Leblond, 
1971). Asymmetric division within a satellite cell sub-population has been 
witnessed to co-segregate all template DNA to one sister cell which is biased to 
self-renewal. This is known as the „immortal strand hypothesis‟, it is presumably 
to prevent accumulation of new mutations within the self-renewing stem cell 
population (Shinin et al., 2006). Alternatively, co-segregation of DNA could be 
due to epigenetic differences between template and new DNA strands, and it is 
this fact that facilitates differential gene expression and divergent cell fates within 
sister cells (Lansdorp, 2007). Either way, the co-segregation of template DNA 
coincides with the sister cell that continues to express Pax7 as well as co-
segregating the Notch inhibitor Numb, promoting self-renewal (Shinin et al., 
2006).  
Functional evidence for satellite cell self-renewal comes from cell 
labelling studies using neo-natal myoblasts from Myf5nlacZ/
+
 mice. These 
myoblasts express a nuclear localising LacZ gene that shows β-galactosidase (β-
gal) activity in each of their donor cells. Following transplantation into post-natal 
skeletal muscle, positive β-gal staining was detected in the host muscle as well as 
within the satellite cell niche. Isolation and culturing of these cells confirmed 
them as functional satellite cells that give rise to myoblasts (Heslop et al., 2001). 
More recently this was re-confirmed:  transplanting a single Pax7
+
/Luciferase
+
 
satellite cell into injured mouse muscle resulted in extensive proliferation that 
contributed to the muscle fibre as well as to mono-nucleated luciferase-expressing 
stem cells (Sacco et al., 2008). Both experiments demonstrate that activated 
satellite cells contribute both to repair and to renewal of the myogenic stem cell 
population (Heslop et al., 2001; Sacco et al., 2008), resulting in the conclusion 
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that the ability to self-renew is autonomous to each muscle satellite cell (Sacco et 
al., 2008). 
In growing or regenerating muscle, asymmetric division gives rise both to 
satellite cells that are disposed to differentiation following fast but limited 
symmetrical replication, as well as to a slowly proliferating population of cells 
that return to G0 between cell cycles and later via symmetric division produce 
larger amounts of myogenic cells than stem cells (Schultz, 1996). In this way a 
small sub-population of satellite cells during activation and replication always 
maintain the myogenic stem cell pool, and thus the majority of myonuclei 
acquired during post-natal myogenesis originate from this pool (Zammit, 2008). 
The rate at which satellite cells proliferate also plays a part in determining their 
fusion capability. The fast-dividing satellite cell population is biased toward 
fusing with pre-existing myofibres (hypertrophy), whereas the slowly dividing 
population responsible for self-renewal predominantly fuses together 
(hyperplasia) (Rouger et al., 2004).  
The heterogeneity seen in the satellite cell population is also seen in 
C2C12 myoblasts that are induced to differentiate, resulting in a population of 
cells committed to terminal differentiation and a population of cells that withdraw 
from the cell cycle. If these latter reserve cells are isolated and re-cultured to 
induce differentiation, this once again results in two populations of cells, a strong 
indication that C2C12 cells are a good in vitro model of satellite cell renewal 
(Yoshida et al., 1998). In addition, C2C12 cells also show the same bias as 
satellite cells in respect to fusion and proliferation rate (Baroffio et al., 1996).  
However, when using C2C12 cells to study satellite cells the natural in vivo 
environment is absent and it has been shown that the satellite cell niche regulates 
many facets of satellite cell function. For example, asymmetric division and thus 
satellite cell renewal is prejudiced towards apical-basal division in regard to the 
orientation of satellite cells within their niche. Therefore, satellite cells that divide 
in the plane of the myofibre instead of perpendicular to it, are inclined to divide 
symmetrically (Kuang et al., 2007). The effect of an absent satellite cell niche was 
demonstrated by grafting isolated satellite cells into the tibialis anterior muscle of 
immunodeficient mdx mice before and after culturing. The regenerative capacity 
of the isolated satellite cells declined considerably if they were cultured before 
grafting. Isolated cells that were expanded in culture were shown to have inferior 
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proliferation and rapid differentiation (Montarras et al., 2005). The satellite cells 
in culture seem to lack self-renewal signals and thus with declining asymmetric 
division, cells gradually become a continuum of satellite cell-derived myogenic 
progenitor cells expressing MyoD. This resulted in the loss of their stem cell-like 
capabilities as they become a homogenous population of myogenic progenitors 
with decreased regenerative capability.  
To summarise the self-renewal process, following satellite cell activation 
and during proliferation, satellite cells progeny can take alternative paths and 
maintain cell numbers via self-renewal. Initially satellite cell activation leads to 
the global expression of MyoD, an eventual decline in Pax7 expression and 
terminal differentiation (Yablonka-Reuveni & Rivera, 1994; Zammit et al., 2004). 
Following replication, an alternative cell fate for satellite cell-derived myoblasts 
results in the down-regulation of MyoD, and maintained Pax7 expression, leading 
to cell cycle withdraw (Zammit et al., 2004). This was further confirmed by 
Pax7
+
/MyoD
-
 satellite cell-derived myoblasts re-expressing quiescence markers 
such as the nestin transgene (Day et al., 2007), and sphingomyelin (Nagata et al., 
2006). Cell cycle withdrawal is facilitated by p21 expression, which if it is 
synchronised with Myf5 expression denotes myoblasts that are returning to 
quiescence, in comparison to p21 expression synchronisation with MyoD 
expression denoting a differentiating myoblast (Kitzmann & Fernandez, 2001). 
The renewing Pax7
+
/MyoD
-
 satellite cell lineage was further investigated 
using MyoD
-
null satellite cell-derived myoblasts. This resulted in amplification of 
stem cell characteristics and of the renewal process, when grafted into 
regenerating muscle. Microarray analysis revealed that in comparison to wildtype, 
MyoD-null myoblasts down-regulated the myogenic determination genes and up-
regulated anti-apoptotic genes, corresponding to increased survival (Asakura et 
al., 2007). Following the myogenic progression of MyoD-null myoblasts during 
muscle regeneration revealed that differentiation does proceed but it is 
substantially delayed due to an extended proliferative period (White et al., 2000). 
This indicates that in the absence of MyoD, a Myf5-directed differentiation 
pathway proceeds, which has been shown to be marked by a delay in myogenin 
expression (Zammit et al., 2006b), with an apparent bias towards quiescence 
(Asakura et al., 2007). It has also been witnessed that following satellite cell 
division, one cell can maintain MyoD expression and commit to terminal 
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differentiation, whereas the other daughter cell can down-regulate MyoD and act 
to replenish the satellite cell pool (Zammit et al., 2004). As MyoD expression can 
be modified epigenetically (Berkes et al., 2004), the above observation strongly 
indicates that asymmetric division is indeed regulated by chromosomal epigenetic 
differences, which facilitates the difference in gene expression between the two 
lineages (Lansdorp, 2007). 
As mentioned previously, Pax7 is the main satellite cell marker, with 
Pax7-null studies further confirming its importance in satellite cell physiology. 
Juvenile Pax7-null mice contain a considerable number of satellite cells 
(Oustanina et al., 2004), possibly specified by the Pax7 paralogue Pax3, which has 
been seen to share functional redundancies (Mansouri, 1998). However, as post-
natal development progresses these numbers decline, resulting in inefficient 
regeneration, therefore demonstrating the heavy involvement of Pax7 in self-
renewal, as well as its role as a requisite for satellite cell survival (Oustanina et al., 
2004). In the absence of Pax7 expression within Pax3-expressing muscle, satellite 
cells were still increasingly lost due to apoptosis, validating the necessity for Pax7 
in satellite cell survival (Relaix et al., 2006). Also, over-expression of Pax7 directs 
proliferating myoblasts to withdraw from the cell cycle by repressing MyoD 
expression, thus promoting the self-renewal pathway (Olguin & Olwin, 2004; 
McFarlane et al., 2006). This inhibition of myogenesis was also seen during an in 
vitro study on human satellite cells, where maintained Pax7 expression prevented 
satellite cell-derived myoblasts from differentiating (Pawlikowski et al., 2009). 
The presence of satellite cells both in Pax7-null juvenile and Pax7-null adult 
skeletal muscle does suggest however that Pax7 is not exclusively involved in 
satellite cell specification (Oustanina et al., 2004). Interestingly, in a different 
study, Pax7-null mice were devoid of functional satellite cells, however, there was 
a separate Pax3-expressing lineage. These cells were defined as myogenic as they 
co-expressed MyoD following injury, resulting in regenerated myofibres (Kuang 
et al., 2006). Instead of being located in the normal satellite cell niche, the Pax3-
positive lineage were found in the interstitial muscle environment: possibly they 
are residue pre-satellite cells that require Pax7 for specification. However, the 
presence of the Pax3-expressing lineage in both Pax7-null and wildtype mice 
suggests that these cells represent a novel myogenic lineage (Kuang et al., 2006). 
 
28 
 
1.4 Skeletal muscle wasting 
 
There are a number of skeletal muscle diseases that result in loss of body 
mass and muscle atrophy. Cachexia, a progressive skeletal muscle wasting 
syndrome, is associated with several disease states, such as cancer, aids, and 
diabetes. The cachexia metabolic response causes specific loss of adipose tissue 
(Argiles et al., 2003) and skeletal muscle mass (Tisdale, 1991). The catabolic 
response of cachexia results in degradation of skeletal muscle proteins, releasing 
amino acids in response to infection and illness, resulting in muscle atrophy 
(Hasselgren & Fischer, 2001).  
Muscle atrophy can also be caused by age-related degeneration of muscle 
mass, with distinct decline in ability to regenerate; a condition known as 
sarcopenia (Rosenberg, 1997). These weaker muscles are more susceptible to 
stress and injury and have an increased recovery time (Doherty, 2003). It is 
thought that the gradual failure of satellite cells to regenerate aged muscle fibres is 
caused by the diminished levels of myogenic activation signals and growth factors 
(Conboy et al., 2005). With an increase in the aging population, sarcopenia is 
becoming more common, increasing the need for a treatment to maintain the 
quality of life in the elderly. Individuals with muscular atrophy suffer many 
complications, such as loss of mobility, fragile bones, susceptibility to infection 
and general loss of health. Consequently skeletal muscle atrophy can be a serious 
life threatening condition, illustrating the importance of finding an effective 
therapeutic cure (Giordano et al., 2003; Argiles et al., 2005). 
Muscular dystrophy disorders, in addition to cachexia and sarcopenia, 
cause muscular atrophy and muscle weakness: a group of inherited disorders that 
can affect the developing embryo as well as post-natal development (Emery, 
1998). Duchenne muscular dystrophy is the most common disorder, carried on the 
X-chromosome and thus normally occurring with males. At childhood the 
disorder causes progressive muscle wasting, which by adolescence has caused 
considerable weakness, leading to premature death (Emery, 2002).  
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1.5 Stem cell therapy 
 
Stem cell therapy is based on treating damaged or diseased tissue through 
application with embryonic stem (ES) cells. These multipotent cells have a large 
potential in self-renewal and differentiation, giving rise to continuous generations 
of cells that can aid in regeneration (Darabi et al., 2008b). Cultures of ES cells 
when induced to differentiate will form embryoid bodies (EB), multi-cellular 
structures consisting of all three embryonic layers (Kubo et al., 2004). Continued 
growth and differentiation results in the EB establishing a variety of specialised 
cell types (Doetschman et al., 1985), including skeletal muscle (Rohwedel et al., 
1994). The main issue preventing the therapeutical use of these cells is the ability 
to purify the correct population of tissue-specific, embryonic-derived cells from 
the differentiating ES cell mass (Darabi & Perlingeiro, 2008).  
 These EB grown in culture lack certain embryonic skeletal muscle 
structures, indicating that specific myogenic inductive signals are lacking, 
resulting in an altered spatial-temporal gene expression and incorrect patterning of 
the paraxial mesoderm (Darabi et al., 2008a). Pax3 has been shown to be a strong 
transcriptional regulator involved in initiating myogenesis in the early paraxial 
mesoderm (Williams & Ordahl, 1994). Pax-positive cells residing in the 
epithelium of the dermomyotome during embryogenesis can give rise to multiple 
lineages (Kardon et al., 2002; Ben-Yair & Kalcheim, 2005), and in the absence of 
Pax3 expression, cells that would form into myogenic progenitors will 
differentiate into alternative tissue such as bone and cartilage (Relaix et al., 2005) 
and adipose tissue (Rudnicki et al., 1993). Furthermore, expression of Pax3 has 
been shown to direct mesenchymal stem cells to differentiate into a myogenic 
lineage (Gang et al., 2008), suggestive that Pax3 could be used to alter ES cell 
transcription and specify a myogenic lineage (Darabi & Perlingeiro, 2008). This 
theory of lineage-specific reprogramming was tested by generating a doxycycline 
(dox) inducible Pax3 over-expressing ES cell line. This experiment was successful 
in inducing MRFs expression and generating ES cell-derived myogenic 
progenitors. However, in vivo injection of these cells into injured tibialis anterior 
(TA) mouse muscle resulted in tumour formation (Darabi et al., 2008a). The 
tumour was defined as a teratoma, which contains undifferentiated cells of 
ectodermal and mesodermal origin (Darabi et al., 2008b). Specific paraxial 
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mesoderm markers, which were up-regulated following Pax3 induction and for 
specified differentiated paraxial mesoderm tissue, were used to purify the ES cell-
derived myogenic progenitors from the undifferentiated ES cell mass. Subsequent 
in vivo injection into mdx mice and immunodeficient mice resulted in the 
restoration of dystrophin expression and myosin heavy chain expression, 
respectively. The purified Pax3 lineage reprogrammed ES cells were successful in 
providing substantial engraftment of myogenic cells, without the formation of 
teratomas (Darabi et al., 2008a), suggestive that stem cell therapy might be used 
in future therapy of muscular dystrophy disorders (Darabi et al., 2008b).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
31 
 
1.6 Aims and Objectives 
 
Myofibre nuclei are post-mitotic and incapable of re-entering the cell 
cycle. Therefore, skeletal muscle growth and regeneration requires a source of 
myogenic progenitors, other than the aforementioned cells. Satellite cells are a 
distinct lineage of quiescent myogenic progenitor stem cells that reside under the 
basal lamina that is present around muscle fibres. When required, satellite cells are 
activated to proliferate and differentiate into myoblasts that contribute to 
increasing muscle mass. The importance of Pax3 during embryonic myogenesis 
and tumorigenesis is well documented:  
 
 Pax3 and proliferation: Pax3-FKHR expression results in the proliferative 
expansion of uncommitted myogenic precursor cells (Kurmasheva et al., 
2005). Furthermore, the proliferative potential of embryonic limb muscle 
progenitor cells decreases if Pax3 is replaced by Pax7 (Relaix et al., 2004). 
 Pax3 and differentiation: Pax3-FKHR expression maintains myogenic 
precursor cells in the cell cycle preventing myogenic commitment and thus 
inhibiting differentiation (Kurmasheva et al., 2005). Pax3 expression also 
prevents pre-mature differentiation of hypaxial progenitor cells during 
limb myogenesis (Bober et al., 1994).  
 Pax3 and survival: Tumour cells expressing Pax3-FKHR have increased 
resistance to apoptosis (Kurmasheva et al., 2005), facilitated through Pax3 
interaction with the anti-apoptotic protein BCL-XL (Margue et al., 2000). 
 Pax3 and migration: Pax3 promotes the migration of hypaxial progenitor 
cells during embryonic myogenesis (Bober et al., 1994), whether Pax3 
plays a similar role in the migration of satellite cell-derived progenitors 
remains to be defined. 
 Pax3 and myogenic gene expression: During embryonic-myogenesis Pax3 
is in direct or indirect control over the myogenic regulatory factors Myf5 
(Bajard et al., 2006) and MyoD (Tajbakhsh et al., 1997), respectively. The 
active post-natal Pax3 protein synthesis regulation pathways indicate a 
similar transcriptional power in post-natal muscle (Boutet et al., 2007; 
Crist et al., 2009).  
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The aim of this study was to elucidate the role(s) of the Pax3 gene in the 
development and regeneration of post-natal muscle. Although the role of Pax3 
during embryonic skeletal muscle development and tumorigenesis is well 
researched, recent evidence cautions against inferring the function of post-natal 
muscle from embryonic studies (Lepper et al., 2009). Furthermore, this same 
study suggested that Pax3 and Pax7 are not required for post-natal myogenesis 
(Lepper et al., 2009). However, there is evidence that suggests an active post-natal 
transcriptional role for Pax3. Pax3 expression is highly regulated during post-natal 
growth, by either miRNA interference (Crist et al., 2009) or proteasomal 
degradation (Boutet et al., 2007). This illustrates the importance of maintaining 
the correct spatial-temporal gene expression of Pax3.  
In this study the role of Pax3 in post-natal myogenesis was investigated via 
a gain of function assay by generating Pax3 over-expressing myoblast (C2C12 
cells) cell lines. C2C12 cells have been shown to have similar population 
dynamics, proliferation and fusion rates as satellite cell-derived myoblasts, 
proving it to be a good in vitro model of post-natal myogenesis (Baroffio et al., 
1996; Yoshida et al., 1998). The effect of Pax3 during proliferation, 
differentiation, survival, migration and myogenic gene expression were analysed 
with Pax3 over-expressing myoblasts to determine whether Pax3 plays an 
analogous role during post-natal myogenesis as observed during embryonic 
myogenesis.  
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Chapter Two: Materials and Methods 
 
2.1 Materials 
 
2.1.1 PCR oligonucleotide primers  
 
All primers were custom synthesised by either Sigma or Invitrogen. Primer 
sequences are listed in Table 1. Oligonucleotides were re-suspended in 100 µl of 
MilliQ water and stored at -20°C. Working primer solutions for PCR were diluted 
to 10 µm with MilliQ water and also stored at -20°C. Invitrogen synthesised Pax3 
primers were used in standard PCR amplification: these were also designed for 
mRNA quantification using semi-quantitative and quantitative PCR analysis.  
 
Table 1 PCR oligonucleotide primers 
 
 
 
2.1.2 Common Solutions  
 
Common solutions used in this study are listed in the Appendix, and were 
prepared exactly as described by Ausubel et al. (1987) and Sambrook et al. (1989) 
 
 
 
 
Gene Primer Sequence (5' TO 3') Product Size (bp) Use
Pax3 Fwd GGATCCATGACCACGTGGCCGGCGC 1437 Standard PCR
Rev GCGGCCGCCTAGAACGTCCAAGGCTTAC
Pax3 Fwd GCCTCAGACCGACTATGCTC 234 RT-PCR
Rev GCGGCCGCCTAGAACGTCCAAGGCTTAC
Myf5 Fwd TGCCATCCGCTACATTGAGAG 353 RT-PCR
Rev CCGGGGTAGCAGGCTGTGAGTTG
p21 Fwd TCCAGGAGGCCCGAGAACG 428 RT-PCR
Rev GCTAAGGCCGAAGATGGGGAAGAG
Tubulin Fwd GCTTCTTGGTTTTCCACAG 450 RT-PCR
Rev TGCTGAGAAAGCCTACC
H3.3A Fwd GGCTCGTACAAAGCAGACTGCC 225 RT-PCR
Rev GCAATTTCTCGCACCAGACG
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2.1.3 Enzymes 
 
Enzymes used in this study are listed below in Table 2. Buffers for 
enzymatic reactions were always supplied with their respective enzyme and were 
used according to manufacturer‟s instructions.  
 
Table 2 Enzymes 
 
 
2.1.4 Antibodies 
 
Antibodies listed in Table 3 were used for either immunocytochemistry or 
Western blot analyses. 
 
Table 3 Antibodies 
 
 
Enzyme Source
Taq  DNA polymerase Roche
FastStart Taq DNA polymerase Roche
T4 DNA ligase Invitrogen
Rnase H Invitrogen
Superscript II Reverse Transcriptase Invitrogen
BamH1 Invitrogen
Not1 Invitrogen
EcoR1 Invitrogen
Apa1 Invitrogen
Primary Antibodies
Antibody Source Description Use
Pax3 DSHB* Monoclonal mouse Western
p21 Becton Dickinson Monoclonal mouse Western
MyoD Becton Dickinson Monoclonal mouse Western
Myf5 Santa Cruz (Global) Polyclonal rabbit Western
Pax7 DSHB* Monoclonal mouse Western
Myogenin Santa Cruz (Global) Polyclonal rabbit Western
Tubulin Sigma Aldrich Monoclonal mouse Western
GapDH Rsearch Diagnostics Monoclonal mouse Western
MyHC DSHB* Mouse ICC
* DSHB - Developmental Studies Hybridoma Bank
Secondary Antibodies
Antibody Source Description Use
P0447 Med Bio, Dako Polyclonal goat anti-mouse Western
P0448 Med Bio, Dako Polyclonal goat anti-rabbit Western
RPN1001V1 Amersham Biotin sheep ICC
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2.1.5 Mammalian cell lines 
 
C2C12 murine myoblasts (Yaffe & Saxel, 1977) sourced from the 
American Type Culture Collection (ATCC) were used for all cell culture 
experiments in these studies.  
 
2.2 Methods 
 
 The initial methods in this chapter describe the standard molecular biology 
techniques used (Sections 2.2.1 – 2.2.6.7). Sections 2.2.7 and 2.2.8 specifically 
detail the use of these techniques in generating a Pax3-pcDNA3 vector, which was 
then transfected into C2C12 cells and clonal cell lines selected. The remaining 
sections describe the methods for functional assays to determine proliferation, 
differentiation, migration and apoptosis (Sections 2.2.9 to 2.2.15) of the Pax3 
over-expressing cell lines and control cells. These techniques were used to 
determine whether Pax3 over-expression altered myoblast function in vitro.  
 
2.2.1 Polymerase Chain Reaction (PCR) 
 
2.2.1.1 Reverse transcription PCR  
 
First strand cDNA synthesis for generation of cDNA templates for PCR 
was prepared using SuperScript First Strand Synthesis System (Invitrogen) 
according to the manufacturer‟s protocol. Two micrograms of total RNA was used 
to prepare all cDNA samples using 1 µl of Oligo(dT)12-18 primers, 1 µl of 10 mM 
dNTPs, made up to 10 µl with DEPC-treated water. This mixture was incubated 
for 5 min at 65°C followed by 1 min on ice. Nine microlitres of reaction mix 
containing 10 × RT buffer, 25 mM MgCl2, 0.1 M DTT and RNaseOUT was added 
to the previous RNA mix and incubated at 42°C for 2 min. Reverse transcription 
was subsequently initiated with the addition of 1 µl of Superscript II reverse 
transcriptase and incubated for 50 min at 42°C. The reaction was terminated at 
70°C for 15 min. Non-specific RNA was degraded following incubation with 1 µl 
RNaseH at 37°C for 20 min and stored at -20°C. 
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2.2.1.2 PCR amplification 
 
PCR amplifications were carried out using Taq DNA polymerase in a 50 
µl reaction mix that contained 1 × PCR buffer, 0.2 µM of both forward and 
reverse primers, 0.2 mM of dNTPs and 2 µl of template. Thermocycling for PCR 
reactions were carried out in a Hybaid MBS 0.5S PCR system (Hybaid, Ashford, 
United Kingdom). Pax3 was the only gene amplified via routine PCR, the PCR 
conditions used were: 90°C for 30 s, 58°C for 1 min and 72°C for 1 min, repeated 
for 35 cycles. The reaction was completed with a final elongation step of 72°C for 
5 min followed by a 4°C cooling period.  Negative controls were also set-up 
containing 2 μl of MilliQ water instead of template DNA to check for 
contamination. Standardisation of PCR amplification was performed on cDNA 
templates derived from tibialis anterior muscle of a 3 week old mdx mouse and a 
Myostatin-null mouse. 
 
2.2.1.3 Semi-quantitative PCR 
 
Semi-quantification of cDNA templates were performed using the same 
materials and method outlined in Section 2.2.1.2. To determine the cycle number 
range that represents the linear increase in amplification, cDNA samples were 
amplified with 20, 25, 30 and 35 cycles of PCR. The resulting amplicons were run 
on 1% agarose gels stained with ethidium bromide as outlined in Section 2.2.2.1, 
for size determination and quantified on a GS-800 calibrated densitometer (Bio-
Rad). The cycle number that allowed for the best quantification over the range of 
cDNA templates to be measured was chosen to be used during experimental work.  
 
2.2.1.4 Quantitative PCR (Real-Time PCR) 
 
Real-Time quantification of cDNA templates were carried out using the 
LightCycler® FastStart DNA MasterPlus SYBR Green kit (Roche) according to 
the manufacturer‟s instructions. Reactions were performed in 20 µl capillaries and 
amplified using the LightCycler 2.0 Carousel-based PCR system (Roche Applied 
Sciences, Nonnenwald 2, 82372 Penzberg, Germany). Real-Time PCR MasterMix 
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was prepared as required: the MasterMix contained the FastStart Taq DNA 
polymerase, reaction buffer, MgCl2, SYBR Green I dye and dNTP mix. 
Capillaries were placed in a pre-cooled capillary lead-block, with 
additional capillaries added for negative control and calibration samples. Reaction 
mixes were made up consisting of 4 µl of MilliQ water, 0.5 µl of both sense and 
antisense primers and 2 µl of MasterMix for each sample to be quantified and then 
aliquoted into the top of each capillary. Three microlitres of cDNA template were 
added to the reaction mix in the capillaries and mixed by pipeting. Capillaries 
were placed in a centrifugation carousel and centrifuged at 700 × g (3000 rpm) for 
5 s in the LC Carousel Centrifuge 2.0 (Roche). The capillaries were transferred to 
the LightCycler 2.0 machine, for amplification and quantification. 
A protocol of pre-incubation and denaturation, quantitative amplification, 
melting curve and cooling was followed under the control of the LightCycler 
software 4.0. All Real-Time PCR analyses completed for these studies used the 
following cycling conditions for quantitative amplification, 95°C for 5 s, 60°C for 
10 s and 72°C for 10 s, for 45 cycles. Melting curves followed amplification, 
following 60 s at 65°C the temperature was increased at a rate of 0.2°C/sec for 
product identification.  
For quantification, standard curves were generated for each primer set 
using serial dilutions of cDNA template derived from actively growing, Pax3 
stable, over-expressing C2C12 cells and non-transfected C2C12 cells. Calibration 
standards were subsequently amplified alongside samples to standardise each run. 
To determine that the melting curve temperature matched the correct product size 
of amplification, following initial amplification of each primer set, capillaries 
were placed in 1.7 ml tubes and centrifuged at 2000 × g for 2 min. The 
amplification products were then run on a 1% agarose gel for size determination, 
as outlined in Section 2.2.2.1. 
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2.2.2 Gel electrophoresis 
  
2.2.2.1 DNA electrophoresis 
 
 Agarose gels (Invitrogen) were prepared appropriate to the size of the 
DNA fragments to be separated, ranging between 0.6 - 1.2%. Gels were made up 
with 1 × TAE, which was also used as the running buffer, and cast in gel boxes 
(Invitrogen), with 300 ng/ml of ethidium bromide added for DNA visualisation. 
Prior to loading, DNA samples were mixed with 10 × DNA loading dye. A 1 Kb+ 
DNA ladder (Invitrogen) was loaded alongside samples for size determination. 
Electrophoresis was carried out at 70-120 V. DNA was visualised under 
ultraviolet (UV) light (312 nm) using a Gel Doc System (Bio-Rad Laboratories, 
Hercules, CA) and photographed. 
 
2.2.2.2 RNA electrophoresis 
 
 RNA was fractionated by electrophoresis on formaldehyde/agarose gels 
and 18s and 28s ribosomal bands were examined to verify the integrity of 
extracted RNA. RNA gels were prepared containing 1% agarose dissolved in 
DEPC-treated water, then 1 × MOPS and 0.66 M formaldehyde was added. Gels 
were cast in Invitrogen RNA gel boxes and run with 1 × MOPS buffer. Initially, 
RNA samples were quantified using the NanoDrop spectrophotometer (ND-1000; 
NanoDrop Technologies Inc., Wilmington, DE, USA). Prior to loading, 2 µg of 
RNA was mixed with an equal amount of RNA loading dye, containing ethidium 
bromide, which was heated to 65°C for 5 min. The desired separation of RNA 
bands was obtained with electrophoresis proceeding at 70 V. RNA bands were 
visualised and photographed using the Gel Doc system (Bio-Rad). The densities 
of 18s and 28s ribosomal bands were measured on a GS-800 calibrated 
densitometer (Bio-Rad) to verify accurate quantification and assess integrity of the 
RNA. 
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2.2.2.3 Protein electrophoresis 
 
To estimate the concentration of protein samples to be separated via 
electrophoresis, a Bradford assay was used (Bradford, 1976).  The Protein Assay 
Dye Reagent (Bio-Rad) was diluted to 1:5 using MilliQ water.  Bovine serum 
albumin (BSA) was used to prepare the standards, ranging in concentration from 0 
to 10 mg/ml. The standards and samples were made up to a volume of 100 µl, 
with the samples containing 1 µl of protein.  The assay reaction mixture contained 
1.2 ml of dye with 100 µL of sample or standard and mixed by inversion.  The 
absorbance was measured at 595 nm using a Heλios UV spectrophotometer 
(Thermo Spectronic, Cambridge, U.K) and protein concentrations were estimated 
from the BSA standard curve.   
Protein electrophoresis was carried out on pre-cast NuPage 4-12% gradient 
Bis-Tris SDS polyacrylamide gels (Invitrogen), using 1 × NuPage MES SDS 
running buffer in Novex Mini Cells (Invitrogen). Following protein estimation 
and prior to loading, 15 µg of each protein sample was boiled for 5 min in the 
presence of a 1:4 β-mercaptoethanol:4 × loading dye. Protein samples were loaded 
alongside a SeeBlue Plus 2 pre-stained standard (Invitrogen) for size 
determination. Electrophoresis was performed at a constant current of 50 mA until 
the desired level of separation was obtained.  
  
2.2.3 Enzymatic Reactions 
 
2.2.3.1 DNA purification 
 
The Promega Wizard DNA purification system was used to purify PCR 
amplicons for cloning. PCR products (50 µl) with loading dye was run on a 0.8% 
low melt agarose gel (Mercury) at 70 V (see Section 2.2.2.1) then specific 
fragments corresponding to expected sizes were excised from the gel under UV 
light using a razor blade. Each excised agarose fragment was heated to 65°C in a 
1.7 ml eppendorf tube for 5 min. 1 ml of Wizard purification resin was mixed with 
the melted gel and extracted DNA. Using a syringe the resin/DNA was purified 
from the agarose by passing through a mini-column and then washing twice in 2 
ml 80% isopropanol. The purified resin/DNA was collected by centrifuging the 
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mini-columns at 10,000 × g for 2 min; purified DNA was eluted following a 1 min 
incubation period with MilliQ water and briefly centrifuging at 10,000 × g.  
 
2.2.3.2 Restriction endonuclease digestion 
 
 Restriction endonuclease digests were performed at 37°C for 1-2 h using 
the appropriate 10 × buffer for the specific restriction enzyme used. 10-20 U of 
enzyme were used for each digest depending on the DNA concentration. 
Following restriction digests, fragment size was verified by gel electrophoresis 
(see Section 2.2.2.1) and specific fragments were purified using the wizard kit 
(see Section 2.2.3.1). 
 
2.2.3.3 DNA Ligation 
 
 Restriction endonuclease digestions on DNA inserts or cloning vectors 
(see Section 2.2.3.2) were used to generate complementary 3‟ and 5‟ extensions 
for cloning. Ligation reactions used 1 U of T4 DNA ligase to clone a 3-fold molar 
excess of purified DNA inserts (see Section 2.2.3.1) into 25-50 ng of linearised 
cloning vector, using the respective 10 × ligation buffer. Ligation reactions were 
performed overnight at 4°C. 
 
2.2.4 Transformation and growth of bacteria 
 
2.2.4.1 Transformation of competent cells 
 
Transformation of E.coli strain DH5α (Invitrogen) and Top10 (Invitrogen) 
cells were performed following ligation reactions (see Section 2.2.3.3). Ligation 
mix (4 μl) was added to a 50 μl aliquot of competent cells, which was incubated 
on ice for 30 min.  The transformation mixture was then heat shocked at 42°C for 
45 s and subsequently placed on ice for a further 2 min.   450 μl of SOC LB 
medium (Invitrogen) was then added to the mixture and incubated in a shaking 
incubator at 37°C for 1 h.  During this time, using aseptic techniques, 100 μl of 20 
mg/ml X-gal and 2.5 μl of 200 mg/ml IPTG were spread onto ampicillin (50 
µg/ml) agar plates.  Following the incubation period, 200 μl of the transformation 
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was also spread onto the same agar plates.  The plates were incubated overnight at 
37°C. 
 
2.2.4.2 Culturing of Bacteria 
 
 Positive colonies that contained the cloning vector following 
transformation (see Section 2.2.4.1) or obtained from glycerol stocks, were seeded 
in 5 ml LB broth containing 50 µg/ml ampicillin. Cultures were grown in 50 ml 
plastic tubes (Nalge Nunc International) for small scale culture and in 1 L flasks 
for large scale culture, at 37°C in a shaking incubator (250 rpm) overnight.  
 
2.2.5 Plasmid DNA extraction 
 
2.2.5.1 Miniprep plasmid DNA extraction 
 
 Following overnight growth of Miniprep cultures (see Section 2.2.4.2), 
cells were lysed and DNA extracted and purified exactly as described by the 
manufacturer‟s protocol (Qiagen, QIAprep spin Miniprep system). Briefly, 
bacteria were harvested via centrifugation at 3500 rpm for 5 min. Buffer P1 (250 
μl) followed by buffer P2 (250 μl) were added to the bacterial pellet. Each sample 
was inverted several times and left to incubate for 5 min. Buffer P3 (350 μl) was 
subsequently added and mixed as previously. The supernatant containing plasmid 
DNA was obtained via centrifugation at 20,000 × g for 1 min and removed to a 
QIAprep spin column, where centrifugation was repeated. Buffer PE (750 μl) was 
used to wash the spin column, which was centrifuged twice to remove any 
remaining buffer. MilliQ water (50 μl) was used to elute the plasmid DNA from 
the spin column, which was collected by centrifugation following a 1 min 
incubation period. 
 
2.2.5.2 Maxiprep plasmid DNA extraction 
 
 Following overnight growth of Maxiprep cultures (see Section 2.2.4.2) 
cells were lysed and DNA extracted and purified exactly as described by the 
manufacturer‟s protocol (Qiagen, plasmid Maxi kit). Cells were harvested from 
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250 ml culture via centrifugation at 6000 × g for 15 min. The pellet was re-
suspended with sequential addition of 10 ml buffer P1, followed by mixing with 
buffer P2 and buffer P3. Re-suspended cultures were incubated on ice for 20 min, 
followed by centrifugation at 20,000 × g for 30 min and 20,000 g for 15 min. The 
supernatant containing plasmid DNA was purified by passing the supernatant 
through a Qiagen column by gravity flow. Retained plasmid DNA was washed 
twice with buffer QC and eluted in the elution buffer. Isopropanol was used to 
precipitate purified plasmid DNA, which was collected via centrifugation at 
20,000 × g for 10 min. The resulting pellet was washed twice with 70% ethanol 
and left to air dry. MilliQ water was used to re-suspend plasmid DNA, with the 
volume determined according to the size of the pellet.  
 
2.2.6 Mammalian Cell Culture  
 
2.2.6.1 Culturing of C2C12 myoblasts 
 
C2C12 cells were maintained in DMEM proliferation medium (Life Technologies, 
Grand Island, NY. USA) containing penicillin (1 × 10
5
 IU/I) and streptomycin 
(100 mg/l, Sigma Cell Culture Ltd, St Louis, MO, USA) and 10% foetal bovine 
serum (FBS) (Invitrogen), buffered with NaHCO3 (41.9 mM/l, Sigma) and 
gaseous CO2. Phenol red (7.22 mM/l, Sigma) was used as a pH indicator. Unless 
otherwise stated, cells were grown and manipulated on 10 cm plates (BD Falcon 
Biosciences Discovery Labware, Bedford, MA) and incubated at an atmosphere of 
37°C, 5% CO2. 
 
2.2.6.2 Differentiation of C2C12 myoblasts 
 
 To induce differentiation of C2C12 cells, medium was switched to 
differentiation medium, which was exactly as described for the proliferation 
medium except that 2% horse serum (HS) replaced 10% FBS.  
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2.2.6.3 Trypsinisation and passage of C2C12 myoblasts  
 
 To passage C2C12 cells, the medium was removed and cells were washed 
twice with phosphate buffered saline (PBS). To detach cells from plate 5 ml of 1 × 
trypsin was added for 30 s at room temperature to washed cells, following which 
4.5 ml of the 1 × trypsin was removed and then the plate was incubated at 37°C 
for a further 10 min. For a routine media change, cells were re-suspended in 3 ml 
proliferation media and added to a fresh plate containing 7 ml of proliferation 
media, while gently swirling. Alternatively, if specific cell densities were 
required, re-suspended cells were quantified using a haemocytometer and diluted 
in the appropriate volume of proliferation media. Freshly plated cells were 
incubated overnight. 
 
2.2.6.4 Transfection of murine C2C12 myoblasts 
 
C2C12 cells were grown as described in Section 2.2.6.1, until 70-80% 
confluent. Lipofectamine 2000 (Invitrogen) was used for transfection of DNA 
plasmids according to the manufacturer‟s instructions. In separate tubes, 800 µl of 
serum-free DMEM was added to each of 12.5 µg of construct DNA (tube 1) and 
40 µl of Lipofectamine 2000 (tube 2). The contents of tube 2 was added drop-wise 
to tube 1 while aeration was applied to tube 1 using an auto-pipette, followed by 
incubation at room temperature for 20 min. The resulting transfection mix was 
gently mixed with 8.4 ml of proliferation medium then pipetted onto a 10 cm plate 
of pre-washed C2C12 cells. Transfected cells were incubated overnight. For a 
transient transfection, a media change with proliferation media was performed the 
following day and transfected cells were incubi ted until they reached 70-80% 
confluence. Protein was then collected using the protocol outline in Section 
2.2.6.7.   
 
2.2.6.5 Selection of stable transfected constructs in C2C12 myoblasts 
 
 C2C12 myoblasts were transfected following the protocol described in 
Section 2.2.6.4. Following overnight incubation, transfected cells were passaged 
(see Section 2.2.6.3) at three separate clonal densities on 10 cm plates (1000 
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cells/plate, 2000 cells/plate and 3000 cells/plate) and incubated for 24 h. 
Transfection of plasmid DNA into C2C12 cells conferred geneticin antibiotic 
resistance allowing DMEM containing geneticin (0.6 mg/ml) to be used to select 
for stably transfected cells. Initially geneticin was added with fresh proliferation 
medium and incubated for 4 d, after which proliferation medium containing 
geneticin was routinely replaced as required. Transfected cells were grown until 
over 75% of the colonies filled the 400 × magnification field of view of a 
compound microscope. Colonies were initially selected by circling the entire 
colony on the bottom of the pate with a fine tip pen. Medium was removed from 
the plate and by gently using a 10 µl pipette individual colonies were scraped and 
removed with 2 µl of media. Each of the transfected colonies were transferred to 
24 well plates and grown in 6 ml of proliferation media containing geneticin. 
When each colony reached sub-confluence (70-80%) they were passaged and 
transferred to a 6 well plate in 4 ml of proliferation media with geneticin, where 
they were maintained as triplicate cell lines.  
 
2.2.6.6 Harvesting RNA from C2C12 myoblasts 
 
 Proliferation medium was removed from cells grown on 6 well plates; the 
cells were washed twice with 4 ml PBS, and a 1 ml pipette was used to ensure 
complete removal of medium and wash. To lyse cells, 1 ml of Trizol reagent 
(Invitrogen) was added to cells and repeatedly rinsed over the well. Trizol lysates 
were collected in 1.7 ml tubes. Trizol lysates were incubated for 5 min at room 
temperature, and then 0.2 ml of chloroform was added per 1 ml of Trizol. Samples 
were shaken vigorously for 15 s and incubated at room temperature for 3 min, 
then phases were separated via centrifugation at 12,000 × g for 15 min. All 
centrifugation during RNA isolation was performed at 2-8°C. The top aqueous 
layer containing total RNA was carefully collected without disturbing lower layers 
and transferred to a fresh 1.7 ml tube. RNA was precipitated using 0.5 ml 
isopropanol for every 1 ml of Trizol originally used and incubated at room 
temperature for 10 min. The RNA precipitate was pelleted by centrifugation at 
12,000 × g for 10 min. Supernatant was removed and the RNA pellet washed with 
1 ml 75% ethanol, followed by vortexing and centrifugation at 7,500 × g for 5 
min. Following the wash, the supernatant was removed and the pellet was air-
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dried for 5 min. Total RNA was re-suspended in DEPC-treated water, the volume 
depending on the size of the pellet, and incubated at 55°C for 5-10 min until 
pellets were re-suspended. Total RNA was stored at -80°C until cDNA was 
generated (see Section 2.2.1.1). 
 
2.2.6.7 Harvesting protein from C2C12 myoblasts 
 
 Proliferation medium was removed from cells grown on 6 well plates; the 
cells were washed twice with 4 ml PBS, and a 1 ml pipette was used to ensure 
complete removal of medium and wash. Cells were scraped off the plate surface 
using 100 µl of protein lysis buffer and transferred to a 1.7 ml tube. Cells were 
passed through a 25 gauge needle ten times to further lyse cells. Cells were 
centrifuged at 13,000 rpm for 2 min, to pellet cellular debris; protein extract was 
collected in the supernatant and stored at -20°C until further analysis (see Section 
2.2.2.3). Cells grown on 10 cm plates were washed in 10 ml volumes of PBS and 
harvested in 200 µl protein lysis buffer.  
 
2.2.7 Generation of Pax3-pcDNA3 over-expressing construct 
 
The 1437 bp murine Pax3 cDNA sequence (NM_008781.3) was amplified 
using standard PCR (see Section 2.2.1.2). Pax3 PCR products were run on a 0.8% 
agarose gel to determine size (see Section 2.2.2.1), and correct sized amplicons 
were wizard purified and eluted in MilliQ water (see Section 2.2.3.1). Purified 
Pax3 PCR products were subsequently ligated into the multiple cloning region of 
a pGEMTeasy vector (Promega) (see Section 2.2.3.3), which was chosen for 
initial cloning due to its ease of ligation with PCR products.  Following ligation, 
the pGEMTeasy cloning vector containing the Pax3 insert was transformed into 
Top10 cells (see Section 2.2.4.1). Plates containing transformed cells were 
incubated overnight at 37°C, and blue/white screening was used to identify 
colonies containing the Pax3-pGEMTeasy cloning vector. The pGEMTeasy 
vector contains a Lac operon that encodes for β-galactosidase enzyme that uses X-
gal as a substrate and IPTG as an inducer.  Successful ligation of Pax3 DNA will 
interrupt the Lac operon preventing X-gal metabolisation and therefore these 
colonies remain white. Positive white colonies were selected and cultured 
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overnight according to Section 2.2.4.2. Purified cloning vector containing the 
Pax3 insert was obtained from the cultured cells using the Miniprep plasmid DNA 
extraction kit (see Scetion 2.2.5.1). To further confirm presence of the Pax3 insert 
within the pGEMTeasy vector an endonuclease restriction digest was carried out 
(see Section 2.2.3.2). Apa1 restriction enzyme was used, which cuts at two sites 
within the Pax3-pGEMTeasy vector: once within Pax3 at 14 bp and once again in 
pGEMTeasy at 1127 bp, resulting in two fragments, a 1165 bp and a 3285 bp 
length of DNA. Miniprep digests were run on a 0.6% agarose gel; presence of the 
two specific DNA fragments confirmed the presence of the insert within 
pGEMTeasy. 
The pcDNA3 expression vector (Invitrogen) was selected to over-express 
Pax3, which was prepared for directional cloning using an endonuclease 
restriction digest with BamH1 and EcoR1 enzymes (see Section 2.2.3.2). The 
Pax3 insert was excised from the pGEMTeasy cloning vector using the same 
BamH1/EcoR1 restriction digest and thus resulting in complimentary 5‟ and 3‟ 
ends. The Pax3 insert was sub-cloned into the linearised pcDNA3 expression 
vector (see Section 2.2.3.3) and subsequently transformed into competent Top10 
cells (see Section 2.2.4.1). Transformed colonies were used as templates for Pax3 
PCR amplification using Pax3 primers (see Section 2.2.1.2). Positive colonies 
determined via colony PCR were cultured overnight (see Section 2.2.4.2). The 
cloned Pax3-pcDNA3 over-expression vector was subsequently harvested using 
Maxiprep plasmid DNA extraction kit (see Section 2.2.5.2). A diagnostic digest 
was used to further confirm the presence of the Pax3 insert, and the restriction 
endonuclease enzyme used was Apa1 (see Section 2.2.3.2). The Apa1 enzyme 
cleaves once within the Pax3 sequence and once within the pcDNA3 vector, thus 
in the presence of the Pax3 insert, two fragments would result from the digest; 368 
bp and 6487 bp. Also, an EcoR1/BamH1 restriction digest was repeated, 
validating Pax3 insert presence by releasing the 1437 bp insert.  
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2.2.8 Generation of Pax3-pcDNA3 over-expressing C2C12 cell line 
 
 The Pax3-pcDNA3 over-expression construct (see Section 2.2.7) and an 
empty pcDNA3 vector were transfected into mammalian C2C12 cells according to 
Section 2.2.6.4. The pcDNA3 over-expression vector is driven by a CMV 
promoter and contains cassettes for geneticin and ampicillin resistance. These 
attributes were used to select for stably transfected C2C12 colonies, according to 
the protocol in Section 2.2.6.5. Protein lysates (see Section 2.2.6.7) and RNA (see 
Section 2.2.6.6) were harvested from stably transfected clones and analysed for 
Pax3 expression using western blot analysis (2.2.11), semi-quantitative PCR (see 
Section 2.2.1.3) and quantitative PCR (see Section 2.2.1.4).  
 
2.2.9 Methylene blue proliferation assay 
 
 Prior to assay, C2C12 cells and Pax3 transfected C2C12 clones were 
grown in DMEM medium as described in Section 2.2.6.1. Cell proliferation was 
assessed in uncoated 96-well Nunc microtitre plates (Roskilde, Denmark). C2C12 
cultures were seeded at 1000 cells/well in proliferation media; each assay 
contained eight replicates of each cell line. After a 24 h attachment period, 
medium was replaced with fresh proliferation medium. Cells were fixed following 
incubation periods of 0, 24, 48, 72 and 96 h. Proliferation was then assessed using 
the colourimetric end point assay described by Oliver et al. (1989). Briefly, 
proliferation medium was removed and cells washed once with PBS then fixed for 
30 min in 10% formol saline. The fixed cells were then stained for 30 min with 
methylene blue (Merck) in 0.01 M borate buffer (pH 8.5, Sigma). Four sequential 
washes with borate buffer removed excess stain. Methylene blue was eluted by the 
addition of 100 ul of 1:1 (v/v) ethanol and 0.1 M HCl. The plates were then gently 
shaken for 30 seconds and the absorbance was read at 655 nm for each well by a 
microplate photometer (BioRad model 3550 microplate reader, BioRad, Hercules, 
CA, USA). Absorbance at 655 nm is linearly proportional to cell numbers.  
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2.2.10 Differentiation Assay 
 
 Prior to assay, C2C12 cells and Pax3 transfected C2C12 clones were 
grown in proliferation medium (see Section 2.2.6.1). Cells were subsequently 
seeded at a density of 20,000 cells/cm
2
. For analysis of protein and RNA, cells 
were seeded on 10 cm plates. For Myosin Heavy Chain (MyHC) 
immunocytochemistry, cells were seeded on Thermonox coverslips (Nunc) inside 
the wells of 24 well plates (Nunc) and on Microtest™ 96 well microtitre black 
walled clear bottom assay plates (Optilux™), for non-fluorescent and fluorescent 
analysis, respectively. Following a 24 h attachment period, C2C12 myoblasts 
were induced to differentiate with the removal of proliferation medium and 
addition of differentiation medium (see Section 2.2.6.1). Plates were incubated for 
up to 96 h, with cells fixed for staining (see Section 2.2.12) or harvested for 
protein (see Section 2.2.6.7) and RNA (see Section 2.2.6.6) at their respective 
times.  
 
2.2.11 Western blot analysis 
 
 Protein samples collected from C2C12 cells and Pax3 transfected C2C12 
clones (see Section 2.2.6.7) were separated on a protein gel as described in 
Section 2.2.2.3. The protein gel was washed with MilliQ water and transferred to 
a Nitrocellulose membrane (Invitrogen) by electroblotting using the Invitrogen 
iBlot™ machine. The transferred membranes were stained in Ponceau for 5 min, 
to verify gel loading accuracy and transfer integrity. Ponceau stain was removed 
through washing with TBST buffer, followed by blocking to prevent non-specific 
binding of antibodies. Membranes were either blocked in 5% skim milk in TBST 
overnight at 4°C or in 0.3% BSA block for 1 h at room temperature. The 
membranes were subsequently probed with the primary antibody, which was 
diluted in the same solution that was used to block the respective membrane. 
Membranes were subsequently washed 5 times with TBST for 5 min, followed by 
incubation with the respective secondary antibody. The secondary antibodies used 
were conjugated to Horseradish Peroxidase (Dako) which used Western Lightning 
(PerkinElmer) Western Blot Chemiluminescence Reagent for detection. 
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Chemiluminescence was performed on the membranes following a final wash 
with TBST.  
 Specific primary and secondary antibody dilutions and incubation times 
for each western blot analysis used are described in Table 4. For more detailed 
description of antibodies refer to Section 2.1.4. 
 
Table 4 Western blot protocols 
 
 
2.2.12 Immunostaining  
 
2.2.12.1 MyHC immunocytochemistry 
 
 Two MyHC immunocytochemistry experiments were performed using 
differentiated C2C12 cell lines, on two different types of plates as described in 
Section 2.2.10. Non-fluorescent visualisation of MyHC immunostaining 
performed on coverslips, used washing volumes of 1 ml and antibody dilution 
volumes of 200 µl. Fluorescent visualisation of MyHC immunostaining performed 
on 96 well microtitre plates, used washing volumes of 200 µl and antibody 
dilution volume of 100 µl.  
Myoblast cultures were washed with PBS buffer before being fixed with 
70% ethanol:formaldehyde:glacial acetic acid (20:2:1) for 30 s, and subsequently 
washed in PBS three times. Cell membranes were then permeabilized in 
PBS+0.1% Triton X-100 at room temperature for 60 min. Cells were washed with 
1 × TBST on a shaking platform at 50-100 rpm at room temperature for 5 min 
prior to blocking with 0.35% carrageenan (Cλ, Sigma, C3889 λ-Carrageenan Type 
IV) in PBS plus 10% normal sheep serum (NSS) for 60 min at room temperature. 
Gene Primary Dil. Incubation Secondary Anti. Secondary Dil. Incubation
MyoD  1:10,000 O/N 4°C PO447 1:5,000 1 hr RT
p21  1:400 3 hr RT PO447 1:2,000 1 hr RT
Myogenin  1:400 3 hr RT PO448 1:2,000 1 hr RT
Pax7  1:500 3 hr RT PO447 1:2,000 1 hr RT
Pax3  1:500 3 hr RT PO447 1:2,000 1 hr RT
Myf5  1:400 3 hr RT PO448 1:2,000 1 hr RT
Tubulin  1:10,000 1 hr RT PO447 1:10,000 1 hr RT
GapDH  1:20,000 1 hr RT PO447 1:20,000 1 hr RT
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Blocking solution was then replaced with the primary antibody, 1:200 dilution of 
mouse anti-MyHC (MF20; DSHB), in Cλ containing 5% NSS, and incubated 
overnight at 4ºC. Cells were then washed with 1 × TBST three times on a shaking 
platform at 50-100 rpm at room temperature for 5 min. The secondary antibody, 
1:300 dilution of biotin sheep anti-mouse (RPN1001VI, Amersham), in Cλ 
containing 5% NSS was added for 60 min at room temperature. Cells were 
washed in TBST as before and incubated with tertiary antibody, which depended 
on the type of nuclear counter-staining to be used.  
Fluorescent assessment of differentiation performed on 96 well Optilux™ 
microtitre plates used a conjugated fluorophor: 1:400 dilution of Alexa Fluor 488 
(Invitrogen) in Cλ containing 5% NSS for 60 min at room temperature. Cells were 
washed with TBS as previously described, and nuclei were counter-stained with 
DAPI at a 1:1000 dilution in PBS for 5 min at room temperature. Cells were 
washed in TBST twice, as previously described, and stored at 4ºC prior to 
visualisation. MyHC-immunostaining and nuclei counter-staining were visualised 
on a Leica DMI 6000B Fluorescence and Light Microscope (Leica Microsystems, 
Heidelberg, Germany), using Leica AF6000 fluorescence system software at 200 
× magnification. To visualise Alexa Fluor 488 immunostained MyHC, an 
excitation filter of 495 nm and emission filter of 519 nm were used. To visualise 
DAPI nuclei stain, an excitation filter of 358 nm and emission filter of 461 nm 
were used. Eight random images were acquired from each of the differentiated 
cell lines, Image-Pro Plus computer software was used to analyse the images, 
which automatically counted the total number of nuclei. Myotube nuclei were 
manually counted from each image; the fusion index was determined by dividing 
the number of myotube nuclei by the total number of nuclei.   
Non-fluorescent assessment of differentiation performed on Thermonox 
coverslips used a DAB chromogen (3,3‟-diaminobenzidine tetrachloride, Sigma 
D-5637): a 1:300 dilution of Steptavidin biotinylated horseradish peroxydase 
complex (RPN1051V, Amersham) in C λ containing 5% NSS for 60 min at room 
temperature. Cells were washed in TBS as previously described, and developed 
with DAB, freshly prepared prior to use. Cells were incubated at room 
temperature for 2-3 min, and the development of a brown precipitate where the 
primary MyHC antibody had bound was monitored under a microscope. The 
reaction was stopped with the removal of the chromogen reagent and cells were 
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washed twice in TBS. Coverslips were transferred to a coverslip rack were 
MyHC-immunostained cultures were counterstained with Gills haematoxylin, 
dehydrated and mounted (see Section 2.2.12.2). 
 
2.2.12.2 Haematoxylin cell staining and Visualisation 
 
 Non-fluorescent MyHC-immunostained cultures on coverslips (see Section 
2.2.12.1) were incubated in 1:1 Gills haematoxylin for 2-4 min and rinsed in 
running tap water, followed by three washes in Scott‟s water for 2 min before 
counterstaining with 1% eosin for 2 min. The cells were then rinsed in running tap 
water before being dehydrated with sequential washes of increasing concentration 
of ethanol (2 × 70%, 2 × absolute ethanol) for 5 min, followed by two washes in 
xylene for 5 min. The coverslips were subsequently mounted onto slides, stained 
cells face down, with DPX solution (BDH) and left to dry for 48 h. 
  Immunostained cellular images were acquired using a Leica CTR 6500 
microscope (Leica Microsystems, Heidelberg, Germany) with 200 × 
magnification. The Leica Microsystems application suite generated a tiling array 
of each coverslip to be analysed (500 images per coverslip). Microsoft Excel was 
used to generate four random numbers; these numbers corresponding to the image 
number in the tiling array, which were checked to ascertain the images selected 
were full and uncompromised. Non-fluorescent analyses of differentiating C2C12 
and Pax3 over-expressing C2C12 clones were performed on coverslips as 
triplicates, with the corresponding 4 images from each coverslip being analysed. 
The four selected images from the original 500 images from each coverslip were 
analysed using Image-Pro Plus computer software; however, myotube nuclei 
number and the total nuclei number were manually counted to determine the 
fusion index. 
 
2.2.13 Apoptosis assay 
 
 A fluorimetric homogeneous caspase assay (Roche) was used to determine 
caspase activity from C2C12 cells, when induced to apoptose by incubation in 
serum free medium in comparison to treatment with proliferation medium (10% 
FBS). Prior to assay, control and Pax3 over-expressing clones were grown as 
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described in Section 2.2.6.1, subsequently cells were seeded at a density of 40,000 
cells/well on Microtest™ 96 well microtitre black walled clear bottom assay 
plates (Optilux™) and incubated for 16 h. Cells were washed three times with 
PBS before addition of treatment media, either serum free or 10% FBS (basal 
apoptosis level), and incubated for 8 h. Two wells were also set-up as reagent 
blank media only, which contained no cells, and two wells were left empty for 
positive controls. Working solutions for the apoptosis kit are unstable and were 
prepared immediately before use: the caspase substrate working solution was 
diluted 1:10 with incubation buffer and positive control lysates were also diluted 
1:10 with incubation buffer. Following the 8 h incubation time, 100 µl of diluted 
positive control lysate was added to the positive control wells, followed by 100 µl 
of diluted substrate working solution being added to each well in the assay. Plates 
were wrapped in aluminium foil and incubated for a further 1-2 h at 37°C. Free 
R110 levels, which are proportional to the amount of activated caspases present, 
were flourimetrically measured following 5 s of shaking, using an excitation filter 
of 499 nm and emission filter of 521 nm on a Bio-Strategy Synergy 2 multi-mode 
plate reader (BioTek Instruments, Winooski, US) using Gen5™ software 
(BioTek). 
 
2.2.14 Migration assay 
 
A migration assay was performed on control and Pax3 over-expressing 
C2C12 clones. The chemo-attractant media used was DMEM containing 2% HS 
plus 5% CEE (optimal) or DMEM containing only 5% CEE (intermediate) or 2% 
HS (suboptimal), a negative control containing only DMEM was also tested. 
Chemotaxis was assessed using cell culture inserts containing polyethylene 
terephthalate 0.8 µm membranes (BD Biosciences, San Jose, CA).  
Prior to assay, insert membranes were treated with 1% Matrigel in DMEM 
for 30 min and left to dry. The above four test media treatments were aliquoted in 
900 µl volumes, into a 24-well plate, the inserts were then placed inside these 
wells. Seventy-five thousand cells were aliquoted in a 350 µl volume into each 
insert and the plates were incubated for 7 h at 37ºC. After incubation, cells 
remaining on the top of the membrane, which had not migrated, were removed 
with pre-wet swabs. A scalpel blade was used to cut the membrane from the 
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insert, which was then fixed in 70% ethanol:formaldehyde:glacial acetic acid 
(20:2:1) for 30 s. The membranes were washed in PBS before being stained in 
Gill‟s haematoxylin for 2 min and subsequently washed twice in Scott‟s water for 
1 min. The membranes were wet-mounted onto slides and viewed using an 
Olympus BX50 Microscope (Olympus Optical Co., Germany) with attached 
camera. Images were taken at 100 × magnification, using Spot Basic software 
(Spot software, Diagnostic Instruments Inc.). 
 
2.2.15 Statistical methods  
 
Data obtained from  multiple wells for Pax3 quantification, proliferation, 
apoptosis and both differentiation assays, were pooled to give a population mean 
(±SEM), and data from multiple experiments had the mean of the mean (±SEM) 
calculated. A one-way analysis of variance (ANOVA) was performed on pooled 
means to determine the level of variance, if the ANOVA analysis was significant 
than comparison between individual means were made. A  Post-hoc T-test was 
used to determine the significant level of difference between control cells and 
Pax3 over-expressing clones.  
For the migration assay, cell counts were averaged for each membrane and 
then averaged again for the total three membranes. A two-way ANOVA was 
performed to determine whether the differences among the four cell lines were 
caused by the three different treatments and not random variation. The two-way 
ANOVA was performed on log transformed cell counts; comparisons with either 
control or optimal treatment were performed using the Dunnetts test.  
All statistical analyses were performed using the Genstat (version 11) 
computer software. 
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3.0 Results 
 
3.1 Stable over-expression of Pax3 
 
3.1.1 Generation of Pax3-pcDNA3 over-expressing construct 
 
The paired box transcription factor 3, Pax3 is a powerful myogenic 
transcriptional controller during embryo-myogenesis (Maroto et al., 1997). 
However, the role of Pax3 in post-natal myogenesis is yet to be fully determined. 
To ascertain whether Pax3 plays an active transcriptional role in post-natal 
myogenesis, or if it acts as a marker for myogenic stemness, stable over-
expressing Pax3-pcDNA3 C2C12 cell lines were generated (see Section 2.2.8). 
The Pax3 1437 bp cDNA (NM_008781) open reading frame was successfully 
amplified from a 3 week old mdx mouse mRNA template and a Myostatin-null 
mouse mRNA template (Figure 3.1a). Pax3 PCR amplicons from both templates 
were subsequently cloned into the multiple cloning site of the pGEMTeasy 
cloning vector. Blue/White screening produced a combination of white and blue 
colonies, of which the positive white colonies were selected. Pax3-pGEMTeasy 
DNA was harvested and purified, and an Apa1 diagnostic digestion was 
performed to confirm the presence of the Pax3 insert in the pGEMTeasy cloning 
vector (Figure 3.1b). Following an EcoR1/BamH1 restriction digestion the Pax3 
insert was sub-cloned into the pcDNA3 over-expression vector. Following 
transformation into competent cells, colony PCR was successful in selecting 
positive colonies through amplification of the Pax3 insert. An Apa1 diagnostic 
digestion further confirmed successful sub-cloning into pcDNA3, as did an 
EcoR1/BamH1 digestion, which released the 1437 bp Pax3 insert (Figure 3.1c). 
 The Pax3 insert in the pcDNA3 vector was sequenced and compared to 
Pax3 sequence (NM_008781). Results revealed that all clones contained one 
common mutation in the Pax3 insert, resulting in an amino acid change of glycine 
being substituted with aspartic acid. This was determined to be a real change, as 
various templates showed the same substitution at amino acid position 419 in the 
coding sequence. This was positively confirmed in the electropherogram as 
resulting from a single nucleotide change of adenine for guanine. The Pax3 
sequence (NM_008781) that was used to design Pax3 primers coded for a 
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transcriptional variant of Pax3. Protein sequences from the Pax3 transcriptional 
variant (NM_008781) and murine Pax3 complete coding sequence (CDS) 
(BC048699) were aligned (Figure 3.1d). Both sequences were identical except for 
the single amino acid substitution at position 140 in the protein sequence and the 
terminal six amino acids. Due to the presence of the single amino acid substitution 
in multiple templates, including the Pax3 CDS, it was determined that this 
mutation was neutral and naturally occurring. As a result, the Pax3-pcDNA3 
construct, which had the insert originally amplified from the 3 week old mdx 
mouse template, was used in all of the experiments reported herein. Recently, the 
National Centre for Biotechnology Information (NCBI) has released an updated 
version of the Pax3 transcriptional variant (NM_008781.4). This Pax3 sequence 
(NM_008781.4) was identical to the Pax3 insert that was cloned into pcDNA3, 
supporting the decision to use this sequence as the Pax3 insert. 
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3.1.2 Generation of stable Pax3 over-expressing cell lines 
 
 Prior to committing to the generation of stable cell lines over-expressing 
Pax3, as it is a lengthy procedure, C2C12 cells were transiently transfected (see 
Materials and Methods Section 2.2.6.4) to generate samples in which to optimise 
Pax3 western blots and determine antibody specificity. Western blot analysis of 
actively growing C2C12 cells transiently transfected with either Pax3-pcDNA3 or 
empty pcDNA3 vector (negative control) showed that the Pax3 over-expressing 
construct produced 1.53 times more Pax3 protein than the control. Protein isolated 
from the transiently transfected cell lines, a Pax7 stable over-expressing cell line, 
and a non-transfected C2C12 control cell line were used to determine cross-
reactivity between Pax3 and Pax7 primary antibodies. The results indicated 
limited cross-reactivity between anti-Pax3 and anti-Pax7 antibodies and their 
paralogues Pax7 and Pax3, respectively (Figure 3.2). There is a possible cross-
reaction, as the 56 kDa Pax3 protein and the lower 54 kDa Pax7 isoform migrated 
to a similiar extent on an SDS-polyacrylamide gel. However, as Pax7 expression 
was not detected in the transient Pax3 over-expressing cells, the cross-reactivity 
was considered inconsequential. 
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Stable transfection of Pax3-pcDNA3 into C2C12 cells, using geneticin to 
select for neomycin resistance and genome integration (see Materials and Methods 
Section 2.2.6.5) resulted in clones that over-expressed Pax3 to a greater extent 
than the transiently transfected cells. A total of 49 Pax3 over-expressing stable 
clones were isolated, as well as a stably transfected empty pcDNA3 vector 
control. All 49 stable transfectants were analysed for Pax3 protein expression by 
western blot analysis. Ponceau staining indicated uneven sample loading in four 
lanes. This result was confirmed following GAPDH analysis; therefore these 
clones (clones 17, 32, 34, and 48) were excluded from further analysis. Pax3 
protein expression levels were normalised to GAPDH expression for the 
remaining 45 clones (Table 5). GAPDH protein expression levels varied 
considerably between the stable clonal cell lines (Table 5). In subsequent assays, it 
was observed that tubulin expression was more consistent among samples and 
therefore tubulin expression was used for western blot normalisation in the 
remaining experiments described herein. 
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A subset of 9 Pax3 over-expressing clones that represented the range, low 
through to high, of Pax3 protein expression were further analysed using semi-
quantitative PCR. PCR amplification was carried out for 25 and 18 cycles, for 
Pax3 and tubulin respectively; the cycle number chosen equated with linear 
amplification of the product (a 234 bp Pax3 fragment and a 450 bp tubulin 
fragment). Pax3 normalised to tubulin expression (Figure 3.3) illustrates that Pax3 
RNA:protein ratios were inconsistent among the Pax3 over-expressing clones.  
Three clones were chosen for further functional analysis: clones 3, 29, and 43. 
Clone 43 was chosen as it exhibited a strong over-expression of Pax3 protein as 
well as having a high Pax3 mRNA profile. Clone 29 was selected as it displayed a 
similar Pax3 RNA:protein ratio as clone 43 but absolute levels of expression were 
intermediate in comparison. This provided the opportunity to investigate whether 
varying levels of Pax3 expression had varying effects on myogenic potential. 
Clone 3 was selected as it displayed the highest over-expression of Pax3 mRNA, 
but with low protein expression.  
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3.1.3 Characterisation of selected Pax3 clones 
  
  Pax3 and Pax7 western blot analyses were performed in three independent 
experiments to obtain an accurate protein expression characterisation of the three 
selected clones, 3, 29 and 43, in comparison to control cell-lines, pcDNA3 and 
C2C12 (Figure 3.4a). Densitometric analysis of the Pax3 Western blots 
normalised to tubulin (Figure 3.4b) shows that the two control cell lines had a 
similar level of Pax3 expression.  Pax3 over-expressing clones expressed 
significantly higher levels of Pax3 protein: clone 3 expressed Pax3 3.4-fold higher 
(P<0.001), clone 29 expressed Pax3 2.2-fold higher (P<0.01) and clone 43 
expressed Pax3 4.1-fold higher (P<0.001). Pax7 western blot analysis showed that 
only control C2C12 and pcDNA3 cell lines expressed a detectable level of Pax7 
protein (Figure 3.4a). 
 Real-Time PCR quantification of Pax3 mRNA was also performed on the 
same cell-lines analysed by Western blot. Histone 3.3A mRNA levels were used 
for normalisation of Pax3 expression. The graph in Figure 3.4b illustrates Pax3 
protein and mRNA expression for each of the cell lines. Absolute levels of Pax3 
mRNA differed between this characterisation of the Pax3 clones quantified by 
Real-Time PCR from the analysis performed using semi-quantitative PCR (Figure 
3.3); however quantitative Real Time PCR is more accurate than semi-quantitative 
PCR. In addition, the trend of protein expression is also different between the two 
experiments. The earlier Pax3 protein quantification via Western blot (Figure 3.3) 
was a singular experiment, whereas this later analysis was performed 3 times and 
thus provided results that could be analysed statistically. Furthermore, GAPDH 
protein expression was used to normalise earlier Pax3 Western blot analysis, 
whereas tubulin protein expression was used for normalisation of this later Pax3 
protein quantification as it proved to be a more reliable method. Therefore, the 
characterisation of the selected Pax3 over-expressing clones and control cells is 
based on the later experimental results. It is also worth noting that this later 
quantification of Pax3 mRNA and protein is analysed relative to the level of Pax3 
expression in control cells, in that C2C12 cells are assigned the arbitrary 
expression value of one. 
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3.2 Functional Analysis  
 
 To assess the role of Pax3 in post-natal myogenesis, the three selected 
Pax3 clones (3, 29, and 43) were assessed in four biological assays: proliferation, 
differentiation, migration and apoptosis. A control cell line, non-transfected 
C2C12 cells, was also analysed for experimental comparison.  
 
3.2.1 Pax3 over-expression slows the proliferation of myoblasts  
 
 The methylene blue proliferation assay was used to assess and compare the 
growth rates of the three over-expressing Pax3 clones with each other and to 
control cells. An altered growth rate due to sustained Pax3 expression, would 
strongly suggest that Pax3 has transcriptional regulatory control over myogenic 
cell cycling. On four separate occasions, a proliferation assay was performed with 
freshly grown Pax3 over-expressing clones and control cells. In decreasing order 
the proliferation assay showed the growth rate as C2C12 > Clone 3 > Clone 43 > 
Clone 29 (Figure 3.5). In the initial 48 h of the proliferation assay, prior to control 
cells reaching confluence, all three Pax3 over-expressing clones exhibited 
significantly slower proliferation rates (Figure 3.5). Once control cells reached 
confluence, all three Pax3 over-expressing clones proliferated significantly faster 
in comparison to control cells for the remaining 48 h (Figure 3.5b). However, 
throughout the proliferation assay, control cells had significantly the highest over-
all growth rate, illustrated in the gradient of the growth curves when comparing 
among Pax3 over-expressing clones and control cells (Figure 3.5a). This data 
strongly suggest that sustained Pax3 over-expression inhibits C2C12 myoblast 
proliferation. Furthermore, this trend was also clearly observable in the difference 
existing between the levels of cell density among the cell lines in all cell culture 
experiments performed prior to experimental set-up 
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3.2.2 Pax3 over-expression delays the differentiation of myoblasts 
 
3.2.2.1 Non-Fluorescent differentiation assay 
 
In order to determine whether Pax3 influences post-natal myogenic 
differentiation, as it does in embryonic limb myogenesis (Bober et al., 1994; 
Goulding et al., 1994; Williams & Ordahl, 1994), and also whether Pax3 induces 
a quiescent, self-renewal pathway, the Pax3 cell lines and control cells were 
exposed to low serum conditions, which are known to induce C2C12 cells to 
differentiate (Blau et al., 1985). In this non-fluorescent assay, differentiation was 
determined by DAB chromogen stained MyHC and cell numbers were obtained 
via Gills hematoxylin staining, and counted manually (see Materials and Methods 
Section 2.2.12.2). Microscope images of three time points; 12 h, 48 h, and 72 h, 
for each cell line (Figure 3.6a) clearly illustrates the delay in differentiation 
exhibited by all Pax3 over-expressing clones in comparison to control cells. The 
fusion index for each cell line for the 48 h and 72 h time points was calculated 
manually by dividing the number of myotube nuclei (myotubes are defined as 
having a minimum of three nuclei) by the total number of nuclei. At both the 48 h 
and 72 h time points the control cells had a significantly higher rate of 
differentiation (Figure 3.6b), reaching 52% fusion at 72 h, in comparison to 32% 
fusion for both clone 3 and clone 43 and only 16% fusion for clone 29. The 
decreasing ability of these cell lines to differentiate follows the same trend 
observed in the proliferation assay: C2C12 > Clone 3 > Clone 43 > Clone 29.  
At the 12 h time point very few myotubes had formed for both Pax3 over-
expressing clones and control cells, however there was clearly an initiation of 
differentiation, observed as mono-nucleated cells expressing the MyHC structural 
protein. Therefore, the proportion of MyHC positive cells was determined instead 
of the fusion index. All three Pax3 clones at 12 h had a higher proportion of 
MyHC expressing cells in comparison to control, with clone 3 (P<0.01) being 
significantly higher (Figure 3.6c).  
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3.2.2.2 Fluorescent differentiation assay 
 
A fluorescent differentiation assay was performed using a fluorescent 
MyHC stain for myotubes and DAPI staining for nuclei (see Materials and 
Methods Section 2.2.12.1). This assay differs from the non-fluorescent 
differentiation assay as it uses a 96 well format instead of 24 well coverslips. 
Furthermore, total cell counts were performed using the Image-Pro Plus computer 
software. This assay is still under experimental optimisation, and it is suspected 
that the automated cell counting program, which estimates the total number of 
DAPI stained nuclei is inaccurate when distinguishing single cells at the late time 
points, when clustering occurs.  
Two time points were tested: 48 h and 72 h, which demonstrated similar, 
but less statistically significant results, than the non-fluorescent differentiation 
assay. Following 48 h of differentiation, the fluorescent differentiation assay 
indicated no significant difference in the fusion index among Pax3 over-
expressing clones and control cells. However, following 72 h of differentiation, all 
three Pax3 over-expressing clones had a significant delay in differentiation in 
comparison to control cells (Figure 3.7b).  
The proportion of MyHC positive cells was also determined for each time 
point (Figure 3.7c), and at the 72 h time point this analysis results in eliminating 
the significant level of difference between Pax3 over-expressing clone 3 and 
control cells, originally seen in the fusion index analysis. Comparison of fusion 
index data to the proportion of MyHC positive cells suggests that Pax3 over-
expression could alter the ability of myoblasts to form mono- and bi-nucleated 
myocytes (hyperplasia) in contrast to the ability to fuse to pre-existing myotubes 
(hypertrophy).  
Overall, this fluorescent differentiation experiment, although showing 
minor changes in differentiation trends in comparison to the non-fluorescent 
differentiation experiment, it does indicate a similar conclusion that over-
expression of Pax3 delays myogenic differentiation. This can be clearly seen in 
the fluorescent microscope images at the 72 h time point (Figure 3.7a).  
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3.2.3 Pax3 over-expression alters C2C12 cell survival 
 
As previously mentioned, during embryonic myogenesis Pax3 is known to 
have an anti-apoptotic effect in the Pax3/Pax7 positive pre-satellite cells (Relaix et 
al., 2006). To determine the anti-apoptotic effect conferred by over-expression of 
Pax3, if any, apoptosis assays were performed. As discussed in the materials and 
methods (see Section 2.2.13), a caspase assay flourimetrically quantified caspase 
activity from the Pax3 clones and C2C12 control following 8 h of serum 
starvation in comparison to cells grown in the presence of 10% FBS. Four assays 
were performed in triplicate for each cell line; two assays were completed on the 
same day with the same cell cultures, confirming assay repeatability. A 
representative caspase assay is shown (Figure 3.8a), with caspase activity being 
proportional to the level of programmed cell death (apoptosis). At basal level of 
apoptosis, when the cells were grown in the presence of 10% FBS, control cells 
had significantly higher susceptibility to apoptosis in comparison to clone 3 
(P<0.001), clone 29 (P<0.01) and clone 43 (P<0.001). Following serum 
deprivation, clone 3 (P<0.001) and clone 29 (P<0.001) remained significantly less 
susceptible to apoptosis in comparison to control cells. However, clone 43 
(P<0.001) displayed a significantly higher level of apoptosis in comparison to 
control cells when deprived of serum. 
The percentage increase in caspase activity from basal levels to levels 
induced by serum starvation was calculated to normalise results to account for cell 
density differences among the four cell lines. The mean percentage change 
represents the average of four assays (Figure 3.8b). This measure indicates the 
susceptibility of cells to serum starvation induced apoptosis. The trend showed 
that both clone 3 and clone 43 were more susceptible to cell death in comparison 
to control cells when serum starved, however, only clone 43 was statistically 
significantly different (P<0.01) to control cells. On the other hand, clone 29 had a 
smaller mean percentage change in cell death following serum starvation in 
comparison to control cells, however the level of difference was not statistically 
significant.  
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3.2.4 Pax3 over-expression promotes C2C12 migration 
 
In response to growth or injury, satellite cells activate and migrate to sites 
of regeneration (Zammit et al., 2006a). To determine whether Pax3 is involved in 
regulating the migration of myogenic cells, a migration assay was performed on 
the Pax3 over-expressing clones and control cells. Three positive control media 
were tested containing chemo-attractants: 5% CEE and 2% HS (optimum); 5% 
CEE (intermediate); 2% HS (sub-optimum). Serum-free DMEM was used as the 
negative control medium. The ability of each cell line to migrate across a porous 
membrane in response to the above treatments was assessed. Three membranes 
were tested per treatment per cell line, with migrated cells being counted on four 
representative fields per membrane. Clustering of migrated cells affected the 
ability to obtain representative fields on certain membranes, especially in the 
control cells. This resulted in larger standard errors, which reduced statistical 
significance among Pax3 clones and the control cells.  
Cell counts were log transformed to normalise variance and a two-way 
ANOVA was performed to compare migration among Pax3 over-expressing cell 
lines and control cells for the three treatments (Figure 3.9a). Both clone 3 and 
clone 29 consistently had a higher average migration for all three treatments in 
comparison to control cells and clone 43, indicating that Pax3 over-expression 
may promote migration. Furthermore, to determine whether Pax3 over-expression 
increased the chemotactic response and sensitivity to chemotactic signals, the 
percentage drop in migration from optimal treatment to intermediate (5% CEE) 
and sub-optimal (2% HS) is illustrated (Figure 3.9b). The migration of all three 
Pax3 over-expressing clones was less affected than that of the control cells by the 
absence of 2% HS in the intermediate treatment, as they were able to migrate 
almost as well even with a reduced chemotactic signal. However, when the 
chemotactic signal was reduced to a sub-optimal level (only 2% HS), the Pax3 
over-expressing clones behaved similar to control cells. Unfortunately, 
statistically there were no significant differences among the four cell lines within 
the two analyses described above. Although this experiment did not provide 
statistically significant results, there was a strong indication that an intermediate 
over-expression of Pax3 (clone 3 and 29) primed cells for migration and increased 
their sensitivity to chemotactic signals. In this experiment the bottom of the 
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membrane inserts was not coated with 1 × Matrigel (a membrane matrix), this 
omission may have caused the clustering of migrated cells and consequently 
higher standard errors. To confirm the trends suggested by these data it is 
recommended the experiment is repeated with Matrigel applied to the bottom of 
the membrane inserts.  
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3.3 Temporal gene expression analysis during myogenic differentiation 
 
3.3.1 Analysis of myogenic transcription during differentiation 
 
There are two pathways a myogenic progenitor can take during 
differentiation, quiescence or fusion, and the specific expression or repression of 
myogenic determination genes determines which pathway is taken (Zammit et al., 
2006b). To determine if over-expression of Pax3 alters temporal myogenic gene 
expression during differentiation, RNA samples were collected every 24 h from 
Pax3 clones and control C2C12 cells throughout a 96 h period of induced 
differentiation and analysed by Real-Time PCR. Analysis was carried out using 
primers designed to amplify Pax3, p21, and Myf5, Histone 3.3A was used to 
normalise for differences in template concentration. Following Real-Time PCR, 
correct amplicon size was verified on agarose gels, which matched to the correct 
fragment length of Pax3 (234 bp), p21 (428 bp) and Myf5 (353 bp), results are not 
shown.  
Due to time constraints, analysis of only one differentiation assay for the 
four cell lines was completed, thus this experiment acts only as an indicator of 
possible alterations in gene transcription caused by the over-expression of Pax3. 
However, each cDNA sample was analysed twice for each cell line, this provided 
a means of assessing the accuracy of each gene transcription analysed via Real-
Time PCR. This is shown as mean normalised expression ±SEM on the 
transcription profiles in Figure 3.10. 
The four cell lines displayed the same profile in Pax3 mRNA expression 
levels as indicated in Section 3.1.3, with all three Pax3 over-expressing clones 
expressing consistently higher Pax3 mRNA in comparison to control cells (Figure 
3.10). Furthermore, both clone 3 and clone 29 up-regulated Myf5 and p21 
transcripts in comparison to control cells. Whereas clone 43, initially displayed 
the same up-regulation in transcription as clone 3 and 29, but at later stages of 
differentiation expressed Myf5 and p21 transcripts at a similar level to control 
cells  (Figure 3.10).  
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3.3.2 Protein expression analysis during myogenic differentiation 
  
In addition to collecting RNA samples, cell lysate samples were also 
collected every 24 h from Pax3 clones and control C2C12 cells through a period 
of 96 h of induced differentiation and analysed by Western blot. The myogenic 
genes analysed were Pax3, p21, Myf5, MyoD and myogenin; tubulin was used to 
normalise for differences in gel loading (Figure 3.11). However, as previously 
mentioned in Section 3.3.1, analysis of only one differentiation assay for the four 
cell lines was completed. Nonetheless, control cell lysates were analysed each 
time with one of the three Pax3 over-expressing clones, this provided a means of 
assessing the accuracy of each gene expression analysed via Western blot. This is 
shown as mean normalised expression ±SEM on the C2C12 expression profiles in 
Figure 3.11b. 
The Pax3 western blot analysis showed that Pax3 clone 43 during the 
course of differentiation was the strongest Pax3 protein expresser, as previously 
demonstrated in Section 3.1.3. The remaining two Pax3 clones, 3 and 29, although 
generally expressing more Pax3 protein than control cells, did not exhibit the 
constant level of Pax3 expression seen in clone 43 (Figure 3.11b); this could be 
due to an active Pax3 protein synthesis regulation pathway. All three Pax3 over-
expressing clones demonstrated elevated levels of Myf5 expression at time 0, in 
comparison to control cells; these levels remained consistently higher in the Pax3 
over-expressing clones during the course of differentiation. Interestingly, the level 
of Myf5 expressed by each cell line paralleled Pax3 protein expression (Figure 
3.11b). MyoD, an important myogenic regulatory factor, showed similar elevated 
levels of expression at time 0 for the Pax3 over-expressing clones 3 and 43 in 
comparison to control cells, while clone 29 displayed a similar level of MyoD 
expression as control cells. Curiously, the peak in MyoD expression for all three 
Pax3 over-expressing clones coincides with peaks in both Myf5 and Pax3 
expression (Figure 3.11b). Furthermore, there was a clear up-regulation of p21 
expression for Pax3 over-expressing clones 3 and 29, with peaks in p21 
expression synchronizing with peaks in expression of the myogenic regulatory 
factor genes, MyoD and Myf5 (Figure 3.11b). Intriguingly, myogenin expression 
profiles for the Pax3 over-expressing clones show an increasing level of 
expression as differentiation proceeds, however, unlike clones 3 and 43, the level 
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of myogenin expressed by clone 29 dropped following the peak in p21 expression. 
In comparison, control cells exhibited a relevantly constant level of myogenin 
expression (Figure 3.11b). 
 Furthermore, to illustrate the synchronization of p21 expression with either 
Myf5 or MyoD, the expression profiles are graphed for each of the Pax3 over-
expressing clones and control cells (Figure 3.12). Pax3 over-expressing clone 3 
and 29 both demonstate a defined synchronization of p21 expression with Myf5 
expression. In comparison, the control cells and clone 43 show a synchronization 
of p21 expression with both Myf5 and MyoD. However, clone 43 consistently 
expresses more Myf5 than control cells. These results require confirmaiton with 
replicate experiments. 
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Chapter Four: Discussion 
 
4.1 Overview 
 
Currently, there are inconsistencies in the literature about the involvement 
of Pax3 in post-natal myogenesis, especially due to its varied spatiotemporal 
expression in post-natal muscle. While most reviews acknowledge that Pax3 is 
expressed by quiescent satellite cells and is also expressed transiently during 
activation, it is the level of expression that creates difficulties in determining the 
role of Pax3 in post-natal myogenesis, as it varies depending on the muscle type  
(Buckingham, 2007; Lagha et al., 2008b; Yablonka-Reuveni et al., 2008). As a 
result, the majority of research has focused on the paralogue of Pax3, Pax7, which 
seems to play a major role in satellite cell physiology. As Pax3 and Pax7 are both 
members of the Pax family of genes, they share similar characteristics in their 
binding to DNA, as described in various studies showing overlapping roles for 
these two genes (Mansouri, 1998; Relaix et al., 2004). In the absence of Pax7, 
regeneration in post-natal muscle progresses, albeit with less efficiency. In this 
scenario Pax3 has been shown to be actively transcribed (Oustanina et al., 2004). 
In addition, a novel Pax3-expressing myogenic population of cells was recently 
described: it is able to regenerate damaged muscle both in wildtype and Pax7-null 
mice (Kuang et al., 2006). These findings show some compensatory mechanisms 
for Pax3 and Pax7; this was also observed in this study, which showed similar 
results to experiments that over-expressed Pax7 in C2C12 myoblasts (McFarlane 
et al., 2006).  
 Pax3 is heavily involved during embryo-myogenesis, where its expression 
regulates the myogenic transcriptional cascade of somite-derived myoblasts 
(Williams & Ordahl, 1994). Furthermore, Pax3 misregulation has been shown to 
be detrimental during post-natal development, with under-expression or over-
expression causing myogenic tumours, known as rhabdomyosarcomas (RMS) 
(Kurmasheva et al., 2005). This strongly suggests that Pax3 has some regulatory 
control during adult skeletal myogenesis.  Pax3 over-expressing C2C12 myoblast 
cell lines were used in this study to investigate the regulatory role played by Pax3 
during post-natal myogenesis. The stable over-expression of Pax3 in actively 
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growing C2C12 cells did not induce the expression of its paralogue, Pax7, 
whereas actively growing control cells exhibited transient expression levels for 
both Pax3 and Pax7 protein. 
 
4.2 Pax3 and Proliferation 
 
 Previous evidence has suggested that Pax3 promotes the proliferation of 
myogenic progenitor cells. For example, the increased transcriptional capacity of 
the Pax3-FKHR translocation gene product results in unspecified myogenic 
expansion of progenitor cells, which causes the formation of RMS tumours 
(Kurmasheva et al., 2005). Furthermore, the proliferative potential of embryonic 
limb muscle progenitors decreases if Pax3 is replaced by Pax7 (Relaix et al., 
2004).  Interestingly, Notch1 signalling promotes the proliferation of Pax3-
positive satellite cells during activation (Conboy & Rando, 2002). More recent 
experimental data also confirms this theory, as constitutive retroviral expression 
of Pax3 was shown to increase the proliferation of C2C12 cells, while expression 
of a dominant-negative form of Pax3 slows cell-division (Collins et al., 2009). It 
was also observed that altering Pax3 expression had an effect on cell morphology, 
with Pax3 over-expression causing a decrease in cell size (Collins et al., 2009).   
 On the other hand, constitutive Pax3 over-expression in the three Pax3 
clones in these experiments strongly suggests that over-expression of Pax3 slows 
C2C12 cell division. The methylene blue proliferation assay showed that the 
control cells reached a significantly higher proliferation rate during exponential 
growth in comparison to all three Pax3 over-expressing clones (Figure 3.5a). One 
limitation of this assay is that cellular methylene blue uptake can be affected by 
cell size (Collins et al., 2009) and thus the Pax3 over-expressing clones could 
absorb less dye, which could be interpreted as slower proliferation. However, 
there was no observable difference in cell size in the over-expressing Pax3 clones 
in comparison to control cells, as seen in Figure 3.6a. In addition, the large 
significant difference witnessed in the growth rates between C2C12 control cells 
and Pax3 clones suggests that this experimental limitation is inconsequential. 
Moreover, the data from the methylene blue assay was always confirmed during 
cell culture work, as C2C12 control cells always had the highest cell density 
82 
 
following seeding and during culture preparation prior to setting up the biological 
assays. 
The contradictory results from two different experiments, retroviral Pax3 
over-expression (Collins et al., 2009) and stably-integrated Pax3-pcDNA3 over-
expression, suggests that the level and length of Pax3 expression has an effect on 
myogenic growth. In the absence of Pax3, via expression of a dominant-negative 
form of Pax3, proliferation is slowed (Collins et al., 2009). This demonstrates that 
Pax3 is required for progenitor cell amplification (Conboy & Rando, 2002), as it 
is required in post-natal muscle for satellite cell activation (Relaix et al., 2006). 
However, the affect of retroviral over-expression of Pax3 on myogenic 
proliferation was only assessed at one time point at 72 h (Collins et al., 2009). 
According to the methylene blue proliferation assay, the growth curve of control 
C2C12 cells has plateaued by 72 h, at which stage Pax3 over-expressing cells are 
still in a linear amplification phase. Furthermore, only actively dividing cells will 
take up the retroviral Pax3 vector, which could have the effect of selecting for a 
colony of cells that are fast dividers. These studies demonstrate that constitutive 
Pax3 over-expression slows the proliferation of C2C12 cells. Furthermore, Pax3 
over-expression has been shown to inhibit myogenic differentiation (Epstein et al., 
1995). Therefore I propose that Pax3 over-expression, whilst slowing cell 
division, will also enhance the ability of myogenic progenitors to expand the 
myogenic population; as their myogenic commitment is inhibited, these cells will 
be maintained in the cell cycle. This is observed during the formation of RMS 
(Kurmasheva et al., 2005). 
 
4.3 Pax3 and Differentiation 
 
In post-natal muscle, Pax3 is transiently expressed during the activation of 
satellite cells (Day et al., 2007), as well as being expressed in quiescent satellite 
cells in specific muscles, such as the majority of forelimb muscles (Relaix et al., 
2006). The expression of Pax3 during satellite cell activation results in an 
intermediate proliferative population of progenitors that are prevented from 
activating the myogenic program (Conboy & Rando, 2002). This has been shown 
in a number of studies, where Pax3 expression prevents initiation of 
differentiation: during limb embryo-myogenesis (Bober et al., 1994; Hammond et 
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al., 2007) and during the formation of RMS tumours (Kurmasheva et al., 2005). 
Furthermore, in vitro over-expression of Pax3 was found to inhibit C2C12 
differentiation (Epstein et al., 1995), as well as delaying the differentiation of 
satellite cell-derived myoblasts (Collins et al., 2009). I obtained similar results 
during MyHC immunostaining of the Pax3 over-expressing clones and control, 
which indicated that over-expression of Pax3 delayed the differentiation of C2C12 
cells, determined by the fusion index (Figure 3.6b and Figure 3.7a). This delay in 
differentiation varied depending on the level of Pax3 over-expression; with Pax3 
clone 29 (the lowest Pax3 protein over-expresser studied) significantly delaying 
the differentiation of C2C12 cells the most. However, there was no complete 
inhibition of myogenic progression, as MyHC expression (an indication of 
terminal differentiation) was detected, at varying levels, in all Pax3 clones after 
only 12 h in differentiation medium (Figure 3.6a and Figure 3.7c).  
It is worthwhile noting that the fluorescent assay, performed on 96 well 
microtitre plates, produced less significant differences in the fusion index between 
Pax3 over-expressing clones and control cells, in comparison to the non-
fluorescent assay, which was performed on Thermonox coverslips. This could be 
caused by the fact that the Optilux™ 96 well microtitre plates used in the 
fluorescent assay, were found to promote the differentiation of myogenic cells 
independently (unpublished data, Developmental Biology Group, AgResearch), 
resulting in an additional exogenous effect influencing cellular differentiation. 
Moreover, as described in the methods and results, the protocol used in the non-
fluorescent assay is more accurate as it has a larger sample size and uses manual 
counting. In comparison, the protocol used for the fluorescent assay, which is still 
under optimisation, uses an automated cell counting program that is affected by 
cell clustering. Thus, results from the non-fluorescent assay were considered more 
significant and indicative of the effect of Pax3 over-expression on C2C12 
myogenic differentiation.  
As determined by the fusion index, all Pax3 clones significantly delayed 
the differentiation of C2C12 cells. However, this significant difference is reduced 
when assessing only the proportion of MyHC-positive cells instead of the fusion 
index, for the same assay.  Curiously, at the 12 h time point, the Pax3 over-
expression clones showed a higher proportion of MyHC-positive cells in 
comparison to control cells. All three Pax3 clones demonstrated the ability to form 
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mono- and bi-nucleated myocytes at a similar or faster rate to control C2C12 cells, 
resulting in growth by hyperplasia (Figure 3.6c and Figure 3.7b). The subsequent 
fusion to form myotubes (hypertrophy) is where the delay in differentiation was 
observed during Pax3 over-expression. This hypothesis was confirmed by data 
that showed that the rate of satellite cell proliferation determines satellite cell 
fusion capability; a fast-dividing population is biased towards fusing with pre-
existing myofibres, a whereas slowly dividing population predominantly fuses 
together to form new fibres (Rouger et al., 2004), with the Pax3 over-expressing 
clones mimicking the slow-dividing phenotype.  
Alternatively, a number of regulation pathways, such as ubiquitination 
resulting in Pax3 proteasomal degradation (Boutet et al., 2007) or miRNA 
interference (Crist et al., 2009) could modulate Pax3 expression levels within the 
over-expressing Pax3 clones, allowing for terminal differentiation. Clone 3, which 
over-expressed Pax3 mRNA the most, but only produced an intermediate level of 
Pax3 protein, could be a candidate for such regulation (Figure 3.4). Pax3 clone 3 
also had the highest proportion of MyHC-positive cells at 12 h, indicating 
myogenic progression (Figure 3.6c). During the course of differentiation, the 
possible effect of either proteasomal degradation or miRNA interference can also 
be seen when comparing the Pax3 protein profiles (by Western blot) of Pax3 
clones and control cells to the Pax3 mRNA profiles (by Real-Time PCR) of Pax3 
clones and control cells (Figure 3.12a). Due to post-transcriptional and post-
translational regulation pathways, it was considered that the proteome of the tested 
cell lines were of more functional importance than mRNA profiles, as protein is 
the final gene product that has a functional effect. 
There are also a number of regulatory pathways that are active during 
embryonic muscle development under Pax3 control, that mediate myogenic 
progenitor cell progression in post-natal muscle. In embryonic muscle, Pax3 
mediates Sprouty1 expression, which in turn negatively regulates Fgfr4 and 
terminal differentiation (Hammond et al., 2007). The importance of Fgfr4 
signalling during post-natal myogenesis has also been demonstrated, with the 
absence of Fgfr4 expression resulting in myogenic cells seeking alternative fates, 
thus undermining muscle regeneration (Zhao et al., 2006; Fukada et al., 2007). 
Following satellite cell activation, Sprouty1 is down-regulated, a possible 
consequent of Pax3 down-regulation. Subsequently, the global expression of 
85 
 
MyoD and the up-regulation of Fgfr4 expression marks satellite cell progenitor 
entry into the myogenic programme (Kastner et al., 2000). It is possible that 
Sprouty1, which has not shown to be under direct Pax3 control in post-natal 
muscle, is down-regulated independently of Pax3, thereby allowing for Fgfr4 
signalling and the myogenic progression of Pax3 over-expression clones.  
A similar situation is observed in the HGF/c-met interplay. In post-natal 
muscle both genes are involved in the activation of satellite cells (Tatsumi et al., 
1998). From an array of growth factors, exogenous HGF was found to initiate the 
proliferation of progenitor cells most efficiently (Gal-Levi et al., 1998) whilst 
inhibiting their terminal differentiation (Miller et al., 2000). In embryo-
myogenesis, HGF and c-met are downstream Pax3 targets, and exhibit a similar 
effect in the repression of differentiation of myogenic progenitors (Lagha et al., 
2008b). Within the in vitro analysis, the lack of a natural in vivo niche, and thus 
the lack of exogenous HGF signalling, could prevent the delay in differentiation 
attributed by Pax3 over-expression. Interestingly, retroviral constitutive 
expression of Pax3 was shown to delay the myogenic differentiation of satellite 
cell-derived myoblasts to a larger extent when the experiment was performed 
within the myofibre niche as compared to in vitro culture (Collins et al., 2009). 
Myogenin expression, indicating commitment to myogenic differentiation, is 
expressed by myogenic progenitor cells as the Pax genes, specifically Pax7, are 
down-regulated (Halevy et al., 2004; Zammit et al., 2004). However, in the Pax3 
over-expressing clones, as the myogenin profiles show (Figure 3.10b), the cells 
are capable of initiating differentiation. This indicates either that Pax3 over-
expression doesn‟t completely inhibit differentiation or that a regulatory pathway, 
which could be Sprouty1/Fgfr4 or HGF/c-met interplay, is interfering with Pax3 
over-expression and promoting terminal myogenic differentiation. Retroviral 
over-expression of Pax3 in C2C12 cells and satellite cell-derived myoblasts 
showed that differentiation does proceed but with a delayed phenotype. 
Furthermore, retroviral expression of a dominant-negative form of Pax3 resulted 
in inhibition of differentiation, suggesting that activation of Pax3 gene targets are 
required for the initiation of myogenic differentiation (Collins et al., 2009).   
C2C12 cells have been shown to behave in a similar manner to satellite 
cells when induced to differentiate; both cell types produce a heterogenic 
population of cells that are either committed to differentiation or to the renewal of 
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the myogenic progenitor population (Yoshida et al., 1998). Asymmetric division 
leads to population heterogeneity, resulting in fast-dividing progenitors that have 
limited proliferation prior to differentiation, and slow-dividing progenitors that 
renew the stem cell population and later, through symmetric division, enhance the 
myogenic population (Schultz, 1996). The Pax3 clones, in comparison to C2C12 
cells, display a significantly lower fusion index, indicating a population of cells 
that is more biased to self-renewal than to differentiation. I propose that over-
expression of Pax3 in C2C12 cells alters population heterogeneity in favour of the 
slowly-dividing self-renewing population of cells. This is also matched by data on 
proliferation, which shows that Pax3 over-expression significantly slows the 
proliferation of cells, for all clones. Furthermore, the Pax3 clones, as mentioned 
above, showed bias towards the formation of mono- and bi-nucleated myocytes 
instead of fusing to form myofibres in comparison to C2C12 cells.  
Gene expression analysis performed on differentiating Pax3 clones and 
C2C12 cells also supported the above proposed hypothesis (Figure 3.10b). At the 
intermediate progenitor stage of post-natal muscle regeneration, once Pax3 
expression becomes down-regulated, MyoD expression marks entry into the 
myogenic program with co-expression of Pax7 (Zammit et al., 2004). Myf5 is 
already expressed by the majority of satellite cell progeny (Zammit et al., 2006b), 
however, Myf5 has been shown to be regulated by Pax3 (Bajard et al., 2006). This 
was confirmed in the Pax3 over-expressing cell lines which were found to express 
Myf5 to a higher extent than control C2C12 cells, with Myf5 expression profiles 
generally matching Pax3 expression profiles, as determined via Western blot. 
Both Myf5 and Pax3 are genetically upstream of MyoD (Bajard et al., 2006), and 
in post-natal muscle, expression of a dominant-negative form of Pax3 and Pax7 
results in repression of MyoD expression (Relaix et al., 2006). However, the 
effect of Pax3 over-expression on MyoD expression is difficult to determine, as 
the expression profiles are similar to those of control cells, as previously shown by 
Epstein et al. (1995). However, MyoD did peak at a higher level in all three Pax3 
clones in comparison to C2C12 cells, which has also been previously 
demonstrated (Collins et al., 2009). This pattern of expression matches hypaxial 
precursor cell gene expression, where these precursor cells require expression of 
both Pax3 and Myf5 to induce MyoD expression (Tajbakhsh et al., 1997), 
suggesting that Pax3 has indirect control of MyoD and that maintained Pax3 
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expression will facilitate MyoD expression as it causes up-regulation of Myf5. In 
addition, this could also place Pax3 in indirect control over Fgfr4 signalling, as 
Fgfr4 signalling has been shown to be transcriptionally regulated by MyoD during 
post-natal myogenesis (Zhao et al., 2006).  
Interestingly, during the course of differentiation, p21 was generally up-
regulated in the Pax3 over-expressing clones in comparison to control cells. This 
could explain the consequent slowing of proliferation observed with Pax3 over-
expression, as p21 caused down-regulation of cell cycle activators, preventing cell 
cycle transition (McFarlane et al., 2006). The synchronisation of p21 up-
regulation (cell cycle withdrawal) with high Myf5 and low MyoD expression 
indicates quiescent, non-differentiating myoblasts, whereas the opposite 
expression pattern, high MyoD and low Myf5 expression, occurs in differentiating 
myoblasts (Kitzmann & Fernandez, 2001). Interestingly, in the Pax3 over-
expressing clones, at 48 h of differentiation, clone 29 demonstrated 
synchronisation of p21 expression with Myf5 expression (Figure 3.11), indicating 
an early withdrawal of progenitor cells from the cell cycle to renew the myogenic 
population. Pax3 clone 3 showed a similar p21 and Myf5 expression profile, but 
peaking at the later time point of 72 h (Figure 3.11). On the contrary, Pax3 clone 
43 did not show a similarly defined expression profile, however, the gradual 
incline in p21 expression exhibited as differentiation proceeded was matched with 
a gradual incline in both Myf5 and MyoD expression (Figure 3.11). This is 
corroborated by the fusion index results, which suggest that clone 29 delays 
myogenic differentiation more efficiently than clones 3 and 43. The expression 
profile of the control cells on the other hand, demonstrated that p21 expression 
synchronised mainly with MyoD expression (Figure 3.11). As it has been 
determined that proliferating cultures become heterogenic in gene expression, the 
high MyoD, low Myf5 expression profile of control cells suggests that the control 
cell line had a higher proportion of differentiating myoblasts that divide 
symmetrically. In rat post-natal muscle regeneration, 80% of progenitor cells 
divided symmetrically and 20% divided asymmetrically (Schultz, 1996). In the 
Pax3 over-expressing clones, up-regulation of Myf5 expression in comparison to 
control cells, in synchronisation with a peak for p21 expression, suggests an 
alteration to this proportional division and indicates that a larger proportion of 
quiescent myoblasts divide asymmetrically. However, there was still a proportion 
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of cells that were fast-dividing and capable of differentiation; as the myogenin 
expression profiles of the Pax3 clones showed (Figure 3.10b), myogenesis still 
proceeded, contrary to previous research (Epstein et al., 1995).  
The differences in results based on Pax3 over-expression in the same cell 
type between this study and Epstein et al. (1995), could be due to differences in 
expression levels of Pax3. The Pax3-FKHR was used by Epstein et al. (1995), 
which has 100 times the transcriptional efficiency of Pax3 in comparison to 
wildtype Pax3 (Bennicelli et al., 1995), as used in this study, which could be 
responsible for the complete inhibition of myotube formation observed by Epstein 
et al. (1995). Although contradictory, both sets of experimental data are mimicked 
during naturally occurring in vivo circumstances. For example, complete 
inhibition of differentiation is witnessed during expression of the naturally 
occurring mutated Pax3-FKHR gene, resulting in the generation of myogenic 
tumours consisting of undifferentiated myogenic progenitor cells (Kurmasheva et 
al., 2005).  In addition, maintained wildtype Pax3 expression in the hypaxial 
domain during embryo-myogenesis is shown to delay differentiation, as seen in 
the Pax3 over-expression clones. Furthermore, primary myocytes are formed in 
the absence of Pax7 expression via a Myf5-directed differentiation pathway 
(Buckingham & Relaix, 2007), which is also possibly occurring in the Pax3 over-
expressing clones. This strongly suggests that the level of Pax3 expression has 
direct influence on myogenic precursor cell fate.  
Research performed by Lepper et al. (2009) showed that stem cells display 
age-dependent changes in their genetic requirement, when comparing embryonic 
and post-natal stem cell biology. Interestingly, the in vitro experiments performed 
in this study, on a post-natal murine cell line, displayed a similar phenotype and 
genotype to embryonic hypaxial precursor cells, which are positive for both Pax3 
and Myf5. Furthermore, Collins et al. (2009) has demonstrated that Pax3 
expression is required for the differentiation of satellite cell-derived myoblasts in 
an in vitro study, whereas, the in vivo study performed by Lepper et al. (2009), 
strongly suggested that post-natal muscle regeneration and growth proceeds in the 
absence of Pax3 and Pax7 regulation. Putting inconsistencies aside, taken together 
this data would suggest that the satellite cell niche plays an important regulatory 
role in satellite cell function, which may bypass the need for Pax3 or Pax7 
expression during post-natal muscle progression.  
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4.4 Pax3 and Survival 
 
During embryo-myogenesis, muscle progenitor survival in the 
dermomyotome and in the developing myotome is supported by the anti-apoptotic 
function of Pax3. In the developing hypaxial somite the anti-apoptotic role of 
Pax3 becomes a requisite for cell survival (Bajard et al., 2006). This is observed 
in naturally-occurring Splotch mutant mice (Pax3-null), which exhibit increased 
apoptosis in the thoracic muscles (Dickman et al., 1999). Confirmation of Pax3 
anti-apoptotic function in embryonic tissue was shown using anti-sense Pax3 
oligonucleotides to disrupt Pax3 expression, resulting in down-regulation of 
MyoD and increased programmed cell death (apoptosis). Some rescue effect was 
observed, when Pax7 was up-regulated in response to the absence of Pax3, also 
resulting in the down-regulation of MyoD (Borycki et al., 1999).   
The Pax-positive myogenic stem cell population that develops into 
quiescent satellite cells requires both Pax3 and Pax7 expression, not only for 
myogenic specification but also for cell survival. In the absence of both Pax3 and 
Pax7 in muscle progenitor cells, extensive apoptosis takes place if cells don‟t 
assume other cell fates (Kassar-Duchossoy et al., 2005). Thus, Pax3 and Pax7 are 
both necessary for the survival of myogenic cells during embryonic and pre-natal 
development. However, during post-natal development, as illustrated by juvenile 
Pax7-null mice, considerable cell death is observed in the satellite cell population 
(Oustanina et al., 2004). This was confirmed in Pax3-expressing muscle, where in 
the absence of Pax7 expression; satellite cells were still increasingly lost due to 
apoptosis, validating the necessity for Pax7 in satellite cell survival (Relaix et al., 
2006). An experiment that knocked-out MyoD illustrated that the Pax3- and Pax7-
positive self-renewing lineage of myogenic cells are increasingly resistant to 
apoptosis. In comparison to wild-type myoblasts, MyoD-null myoblasts down-
regulate myogenic determination genes and up-regulate anti-apoptotic genes, 
corresponding to increased cell survival (Asakura et al., 2007). Quiescent satellite 
cells transiently express Pax3 and are negative for MyoD expression (Relaix et al., 
2006), thus reflecting the above situation, which suggests that Pax3 also plays an 
anti-apoptotic role during post-natal myogenesis, maintaining the satellite cell 
population.   
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Pax3 over-expression through fusion with the Forkhead gene (Pax3-
FKHR) (Bennicelli et al., 1995) results in an oncogenic effect provided by its anti-
apoptotic function, which results in resistance to cell death and to the formation of 
myogenic tumours (RMS). The anti-apoptotic function of Pax3 is obtained 
through its interaction with the anti-apoptotic gene BCL-XL. Ectopic expression 
of either Pax3 or Pax3-FKHR in primary human myoblasts and fibroblasts 
induces BCL-XL expression (Margue et al., 2000). Interestingly, the less 
transcriptionally active form of Pax3, in comparison to Pax3-FKHR, induced 
higher levels of BCL-XL expression, suggesting that lower levels of Pax3 result in 
a larger up-regulation of BCL-XL and therefore increased cell survival (Bennicelli 
et al., 1996; Margue et al., 2000).  
The above described data match the results reported in this study, which 
indicated that the lowest Pax3 over-expressing clone, clone 29, had consistently 
lower activation of caspase activity with treatment in both 10% FBS and with no 
serum (Figure 3.8a), and therefore a lower level of apoptosis. Furthermore, clone 
29 had the overall lowest percentage increase in cell death caused by serum 
starvation in comparison to the other Pax3 over-expressing cells and control cells 
(Figure 3.8b). By comparison, clone 3 and clone 43, both the strongest Pax3 over-
expressers, exhibited the highest percentage activation of caspase activity in 
comparison to control cells following serum starvation (Figure 3.8b). In addition, 
clone 43, the highest Pax3 over-expresser, exhibited significantly higher cell death 
above that of control cells when serum starved (Figure 3.8a). Moreover, the level 
of survival exhibited by the individual clones also seems to be directly related to 
the level of myogenic commitment displayed by each clone, determined by the 
level of MyoD and myogenin expression. During the course of differentiation, 
Pax3 over-expressing clone 29 generally showed a lower level of MyoD and 
myogenin expression in comparison to control cells and Pax3 over-expression 
clones 3 and 43, while exhibiting the highest resistance to apoptosis.  
As both Pax3 and Pax7 offer an anti-apoptotic function to myogenic cells, 
the control C2C12 cells used in the apoptosis assay were analysed for the level of 
Pax3 and Pax7 expression. Western blot analysis indicated transient expression 
levels for both Pax3 and Pax7 for the control cells (Figure 3.2), whereas the same 
Western blot expression analysis on the Pax3 clones indicated no detectable 
expression of Pax7. Thus, the results suggest that the transient expression of both 
91 
 
Pax3 and Pax7 offers a larger survival effect than the over-expression of Pax3 
alone. However, as shown by clone 29, a specifically low level of Pax3 
expression, above that of a transient expression level, provides a significantly 
higher survival than transient expression of both Pax3 and Pax7. Taken together, 
the data suggest that, Pax3 has an anti-apoptotic function, most likely mediated 
through its target gene BCL-XL in a dosage dependent manner (Margue et al., 
2000), and that in post-natal muscle this anti-apoptotic effect of Pax3 is increased 
if co-expressed with Pax7. 
 
4.5 Pax3 and Migration 
 
During embryo-myogenesis Pax3, through its targets c-met and SF/HGF, 
is vital for the delamination and migration of myogenic progenitor cells to sites of 
limb myogenesis (Epstein et al., 1996; Birchmeier & Brohmann, 2000). During 
post-natal muscle regeneration, satellite cells are activated and migrate to sites of 
injury, but the role played by Pax3 during this process remains to be determined. 
It is known that satellite cells and their proliferating progeny express the c-met 
receptor following activation (Cornelison & Wold, 1997). In addition, the 
surrounding basal lamina satellite cell niche contains diffusible HGF growth 
factor, which is released in active form following injury (Tatsumi & Allen, 2004). 
It has been postulated that HGF could be involved in lamellipodia formation, 
implicating its involvement in cell migration (Kawamura et al., 2004; Salerno et 
al., 2009). Furthermore, Notch signalling, activated in response to growth and 
injury, up-regulates transient Pax3 expression (Conboy & Rando, 2002), which 
could be involved in mediating satellite cell progenitor migration to sites of injury.  
The chemotactic assay used to analyse the migrational abilities of the cells 
indicated that a specific level of Pax3 over-expression may enhance the migration 
of C2C12 myoblasts in comparison to control C2C12 cells. This difference in 
migrational ability between Pax3 over-expressing clones and control cells was 
amplified when fewer chemoattractants were used within a treatment, such as 
when only 5% CEE was used in comparison to the combination of both 5% CEE 
and 2% HS (see Section 3.2.4). The level of Pax3 expression could have an effect 
on migrational ability, as Pax3 clone 43 (expressing the most Pax3 protein) 
migrated less than control cells (Figure 3.9). On the other hand, this could be due 
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to an increased sensitivity to apoptosis (demonstrated by Pax3 clone 43) as 
determined by the apoptosis assay performed (Figure 3.8), as cells are kept in the 
absence of serum on the upper chamber during the migration assay. However, 
Pax3 clone 3 also demonstrated a higher susceptibility to apoptosis in comparison 
to control cells, whilst still exhibiting the best chemotactic ability. This suggests 
that a biphasic relationship exists between Pax3 expression and migration, similar 
to the one existing for the level of Pax3 expression and survival.  
The over-expression of Pax3 in two clones (clone 3 and clone 29) resulted 
in an increase in migration for the majority of the treatments in comparison to 
control cells, suggesting that Pax3 plays an active transcriptional role in myoblast 
migration. Even though this experiment did not provide results that were 
statistically significant, it did suggest that an intermediate over-expression of Pax3 
(clones 3 and 29) in comparison to transient expression (control cells) or large 
over-expression (clone 43) of Pax3 prepared cells for migration and increased 
their sensitivity to chemotactic signals. Therefore, it is not unreasonable to 
consider that, in post-natal muscle, Pax3 could mediate satellite cell activation by 
regulating the HGF and c-met signalling pathways, and also by mediating the 
inhibition of myogenic differentiation to promote the migration of satellite cell-
derived progeny to sites of injury.   
 
4.6 Concluding Remarks 
 
 Recent in vivo research has investigated the roles played by Pax3 and Pax7 
in skeletal muscle formation and regeneration. As previously indicated, Pax3 is 
the master myogenic transcription factor during embryo-myogenesis, and Pax7 
acts as the major myogenic transcriptional factor during peri-natal and juvenile 
muscle development. However, inactivation of Pax3 and Pax7 expression during 
post-natal development results in normal regeneration processes proceeding, 
indicating that adult satellite cells do not require either Pax3 or Pax7 for post-natal 
myogenic specification (Lepper et al., 2009). To the contrary, Pax3 expression has 
been detected in specific post-natal muscles, such as the diaphragm, trunk and 
limb muscles; expressed in quiescent satellite cells and transiently during satellite 
cell activation (Relaix et al., 2006). Isolated satellite cells from these muscle types 
showed regenerative capacity when grafted into the tibialis anterior muscle of 
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immunodeficient mdx mice (Montarras et al., 2005). Expression of Pax3 in these 
specific muscle types indicates that Pax3 is either involved in the muscle 
regeneration process or acts as a muscle-specific stem cell marker. However, 
dominant-negative expression constructs of Pax3 have indicated an active 
transcriptional role for Pax3, as the construct prevented C2C12 cells, as well as 
satellite cell-derived myoblasts, from initiating the myogenic program (Collins et 
al., 2009). Similarly, Pax7 has also been proven to be important in post-natal 
myogenesis, for precursor cell specification, and for satellite cell self-renewal 
(McFarlane et al., 2006; Relaix et al., 2006), as Pax7-null studies have shown that 
regeneration is severely compromised in the absence of Pax7 (Oustanina et al., 
2004). However, regeneration has been shown to proceed, facilitated by a novel 
Pax3-expressing lineage present in the interstitial muscle environment in both 
Pax7-null and wildtype muscle (Kuang et al., 2006). The regenerative ability of 
this novel Pax3 lineage does result in reduced myogenic differentiation in the 
absence of Pax7, indicating that co-expression of Pax7 enhances muscle stem cell 
specification (Seale et al., 2004; Kuang et al., 2006). In this novel, interstitial 
Pax3-expressing myogenic lineage it was found that Pax3-positive precursor cells 
can generate up to 5% of the MyoD-positive cells in wildtype muscle (Kuang et 
al., 2006). 
 The results from this study indicate that over-expression of Pax3 in a post-
natal mouse cell line model activates a myogenic precursor state, as witnessed 
during transient Pax3 expression in satellite cells (Conboy & Rando, 2002). 
Continued Pax3 expression would maintain cells in the precursor state, suggesting 
that in vivo this may occur to promote the migration of satellite cell-derived 
precursor cells to distal sites of injury. The hyperplasia observed during 
differentiation of the Pax3 over-expressing clones is possibly induced by a Myf5-
directed differentiation pathway, as observed in embryo-myogenesis during 
primary differentiation (Buckingham & Relaix, 2007). As myogenic specification 
is not completely reliant on Pax7 (Kuang et al., 2006), maintained Pax3 
expression can result in myogenic specification via MyoD expression, although at 
a reduced rate. In the Pax3 over-expressing clones, this smaller proportion of 
committed progenitors, obtained via MyoD expression provides myogenic growth 
via hypertrophy, and is responsible for the myotubes formed during low serum 
induced differentiation. I propose that for efficient hypertrophy, Pax7 expression 
94 
 
is required and that at this stage during in vivo myogenic growth Pax3 would have 
been down-regulated to prevent further delay in myogenic differentiation. 
Whereas with sustained expression of only Pax3, which will result in a small 
proportion of cells that express MyoD, a similar delay in differentiation is 
observed in MyoD-null myoblasts (White et al., 2000). Thus, if Pax3 expression is 
maintained, this could result in an increase in the propensity of cells that enter the 
G(0)-phase of the cell cycle between mitotic division, increasing the proportion of 
cells that divide asymmetrically and express Myf5. Therefore, in comparison to 
control cells, Pax3 over-expression delays the differentiation phenotype, as its 
over-expression increases the proportion of cells that self-renew. The satellite cell 
progeny that renews the myogenic stem cell population will be negative for MyoD 
expression, which has been shown to result in an up-regulation of anti-apoptotic 
genes (Asakura et al., 2007), resulting in increased cell survival. The delay in 
differentiation observed with the over-expression of Pax3 could also be caused by 
the slower rate of cell division, and thus an extended proliferation period is 
required to allow the cells to reach confluence.  
 Population heterogeneity could be introduced by the proteasomal Pax3 
degradation pathway via ubiquitination (Boutet et al., 2007), or miRNA 
interference via miR-27b (Crist et al., 2009), resulting in the small subset of cells 
that express MyoD. Research into both pathways of Pax3 regulation suggest a role 
for Pax3 in post-natal myogenesis, as interference of either pathway results in 
satellite cell-derived myoblasts continuing to proliferate as differentiation is 
delayed, due to the continued expression of Pax3 (Boutet et al., 2007; Crist et al., 
2009). There is considerable evidence to indicate a role for Pax3 in post-natal 
myogenesis, such as aberrant Pax3 expression resulting in numerous abnormal 
muscle conditions (Chalepakis et al., 1994; Underhill, 2000) or myogenic tumours 
(Bennicelli et al., 1995; Kurmasheva et al., 2005), indicating the importance of 
the correct spatial-temporal Pax3 protein expression in post-natal myogenesis. The 
lack of in vivo research confirming the role of Pax3 during regeneration could be 
made more difficult by the specific localised expression of Pax3 and the 
proteasomal degradation pathway that would eliminate any trace of Pax3 
expression. In addition, as the majority of the experiments performed show, the 
effects of Pax3 expression is dosage dependent, demonstrating threshold effects, 
similar to those seen with other Pax proteins in the literature (Buckingham, 2007). 
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The naturally-occurring level of Pax3 expression detected during post-natal 
myogenesis has been described as transient, demonstrating its strength as a 
myogenic transcriptional regulator.  
 As there is conflicting research on the involvement of Pax3 in post-natal 
myogenesis, more research is required to determine its role. An in vivo analysis of 
distal skeletal muscles following injury could possibly emphasize the action of 
Pax3, as its expression is maintained to allow for precursor cell migration. In this 
situation, satellite cells might replicate the hypaxial Pax3-positive precursor 
population during embryo-myogenesis. In addition, research into regulation 
pathways involved with mediation of post-natal progression would be informative, 
such as sprouty1/Fgfr4 or HGF/c-met interplay, as both pathways have been 
previously shown to be under Pax3 control. If Pax3 is actively involved in the 
post-natal regeneration process, its transcriptional power and myogenic potential 
are questions that offer a possible strategy for muscle atrophy and dystrophy 
therapy. Over-expression of Pax3 could provide a population of myogenic 
progenitors that are biased to replenish the myogenic stem cell pool, while 
providing hyperplasia for myogenic growth. Furthermore, this therapeutic strategy 
has the advantage of two naturally-occurring protein synthesis regulation 
pathways that could be used to mediate Pax3 expression levels.  
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Appendix 
 
Common Solutions: 
 
Agarose 
0.5 g UltraPure agarose (Invitrogen) 
50 ml 1 x TAE buffer 
Boiled until agarose is dissolved.  
1 µl 10 mg/ml ethidium bromide per 50 ml Agarose. 
  
 Denaturing RNA agarose gel 
0.6 g agarose 
36 ml DEPC treated water 
Boil to dissolve agarose then cooled to ~60
o
C 
In fume hood add: 
5 ml 10 x MOPS 
9 ml formaldehyde 
  
DEPC (diethyl pyrocarbonate)-treated water 
2 ml DEPC 
2 l MilliQ water 
Mixed overnight then autoclaved. 
 
DNA 1kb+ Ladder 
90 µl 10 x DNA loading dye 
810 µl MilliQ water 
100 µl 1 µg/ml 1kb+ ladder 
  
DNA Loading Dye (10 x) 
10 ml 50% glycerol 
2 ml 50 x TAE 
Pinch of bromophenol blue 
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Eosin (1% solution) 
10 g Eosin Y 
1 l MilliQ water 
2.0 ml acetic acid (5% aqueous) 
1 crystal of thymol 
 
Gill‟s Haematoxylin 
4.0 g Haematoxylin 
0.4 g sodium iodate 
35.2 g aluminium sulphate 
710 ml MilliQ water 
250 ml ethylene glycol 
40 ml glacial acetic acid 
 
Matrigel 
200 μl Matrigel 
1800 μl DMEM 
Bottom of plate is covered, excess is removed. Plate kept at 37
o
C to allow 
Matrigel to set. 
  
MOPS (10 x) Solution (3-[N-Morpholino]propane-sulfonic acid) 
41.8% MOPS powder 
50 mM sodium acetate 
10 mM EDTA 
  
 
PBS (Phosphate Buffered Saline) 
1 PBS tablet (Oxoid) 
100 ml MilliQ water 
  
PBS (10x) 
1 PBS tablet 
10 ml MilliQ water 
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Ponceau S stain 
0.1% Ponceau S 
0.1% Acetic acid 
Make up to desired volume with MilliQ water 
  
Protein loading buffer 
3 parts 4 x NuPage sample buffer 
1 part β-mercaptoethanol 
 
Protein lysis buffer 
50 mM Tris (pH 7.5) 
250 mM sodium chloride 
5 mM EDTA 
0.1% NP-40 
1 x Protease inhibitor 
  
RNA Loading Dye (2 x) 
2 ml MOPS (10 x) 
2 ml deionised formaldehyde 
5 ml deionised formamide 
40 µl of 10% bromophenol blue 
1 ml glycerol 
100 µl of 0.5 M EDTA (pH 8.0) 
40 µl of 10 mg/ml ethidium bromide 
  
RNA running buffer 
1 part 10 x MOPS 
9 parts DEPC water 
  
Scott‟s tap-water 
2.0 g sodium bicarbonate 
20.0 g magnesium sulphate 
1 l MilliQ water 
1 crystal of thymol 
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TAE (Tris-acetate EDTA) for DNA gels (50 x) 
242 g Tris (base) 
57.1 ml glacial acetic acid 
100 ml 0.5 M EDTA (ph 8.0) 
Made up to 1 l with MilliQ water 
  
TBS (Tris buffered saline) 
50 ml 1 M Tris 
30 ml 5 M Sodium chloride 
Made up to 1 l with MilliQ water 
  
TBS-T (Tris buffered saline + Tween-20) 
999 ml TBS 
1 ml Tween-20 
 
Western blocking buffer 
0.15 g BSA 
0.5 g PVP 
0.5 g PEG 
50 ml TBS-T 
  
20:2:1 fixative 
20 parts 70% ethanol 
2 parts 40% formaldehyde 
1 part glacial acetic acid 
 
75% ethanol 
75 ml 100% ethanol 
25 ml DEPC-treated water 
 
0.35% Carageenen-lambda 
0.175 g Carageenen from seaweed (Sigma) 
50 ml PBS 
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1X SDS running buffer  
50 ml 20X NuPAGE™ MES SDS Running Buffer (Invitrogen) 
950 ml dH2O 
10X Trypsin 
2.5% trypsin in PBS 
Bacterial growth media 
LB media 
Bacteria were grown in LB Broth (Lennox L Broth) which was prepared 
by adding 20 g LB Broth base to 1 L H2O, then autoclaved and stored at 4°C. 
 
LB plates 
Bacterial colonies were grown on LB Agar (Lennox L Agar) plates. LB 
Agar plates were prepared by adding 32 g LB Agar to 1 L H2O, followed by 
autoclaving. Molten LB Agar (20 ml) was poured into Petri dishes (10 cm; Nunc) 
and left to set before storing at 4°C. 
 
Cell culture media 
 
Na HCO3 Stock solution 
22 g NaHCO3 
500 ml H2O 
0.32 ml 0.5% phenol red  
 
DMEM 
50 ml 2× DMEM 
8 ml HCO3- 
1 ml penicillin G (200 U/ml) and streptomycin (200 µg/ml) 
41 ml H2O 
 
Proliferation medium 
10 ml FBS 
90 ml DMEM 
 
101 
 
Differentiation medium 
2 ml HS 
98 ml DMEM 
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